Vorinostat (SAHA, MK0683)

Catalog No.S1047 Synonyms: SAHA, MK0683, suberoylanilide hydroxamic acid

Molecular Weight(MW): 264.3

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.

Cited by 100 Publications

Nature, 2011, 471(7337):235-9

PubMed: 21390130

Nat Biotechnol, 2015, 10.1038/nbt.3130

PubMed: 25751058

Nat Biotechnol, 2011, 29(3):255-65

PubMed: 21258344

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062

Cell, 2014, 158(5):989-99

PubMed: 25131989

Sci Transl Med, 2014, 6(256):256ra135

PubMed: 25273096

Blood, 2013, 123(5):706-16

PubMed: 24319254

Nat Struct Mol Biol, 2013, 20(3):317-25

PubMed: 23377543

Nat Commun, 2014, 5:3361

PubMed: 24553445

Brain, 2011, 134(Pt 8):2408-21

PubMed: 21772061

J Exp Med, 2012, 209(1):35-50

PubMed: 22231305

EMBO Mol Med, 2015, 10.15252/emmm.201404396

PubMed: 25872941
EMBO Mol Med, 2015, 10.15252/emmm.201404580

PubMed: 25759362

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2701

PubMed: 25813020

Clin Cancer Res, 2014, 10.1158/1078-0432.CCR-14-0384

PubMed: 25355930

Clin Cancer Res, 2012, 18(14):3822-33

PubMed: 22623731

Clin Cancer Res, 2012, 18(2):408-16

PubMed: 22038994

Clin Cancer Res, 2011, 17(9):2819-29

PubMed: 21357681

Clin Cancer Res, 2011, 17(16):5311-21

PubMed: 21724551

Proc Natl Acad Sci USA, 2013, 111(3):E364-73

PubMed: 24395801

Genes Dev, 2011, 25(24):2610-8

PubMed: 22016339

PLoS Biol, 2013, 12(1):e1001758

PubMed: 24409098

Cancer Res, 2012, 72(9):2251-61

PubMed: 22422937

Blood Cancer J, 2015, 5:e312

PubMed: 25978432
Cell Rep, 2013, 5(6):1679-89

PubMed: 24360956

Cell Death Differ, 2012, 19(12):2029-39

PubMed: 22858545

Cell Death Differ, 2012, 19(8):1317-27

PubMed: 22322857

Int J Cancer, 2015, 136(11):2717-29

PubMed:

Int J Cancer, 2014, 135(7):1721-32

PubMed: 24615207

Int J Cancer, 2013, 132(9):2200-8

PubMed: 23024001

Diabetes, 2014, 63(9):2924-34

PubMed: 24722245

Eur J Cancer, 2012, 48(7):1096-107

PubMed: 22154545

Oncogene, 2013, 33(33):4265-72

PubMed: 24292675

Oncogene, 2013, 32(10):1316-29

PubMed: 22543582

Cancer Lett, 2014, 10.1016/j.canlet.2014.10.034

PubMed:

Cancer Lett, 2014, 351(1):50-8

PubMed: 24814395
Sci Signal, 2010, 3(146):ra80

PubMed: 21045206

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454

Diabetologia, 2012, 55(9):2421-31

PubMed: 22772764

J Neurosci, 2011, 31(11):3990-9

PubMed: 21411642

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437

Cell Death Dis, 2014, 5:e1177

PubMed: 24743732

Cell Death Dis, 2013, 4:e733

PubMed: 23868066

Cell Death Dis, 2013, 4:e951

PubMed: 24309938

FASEB J, 2012, 26(7):3032-41

PubMed: 22459148

Acta Neuropathol Commun, 2015, 3(1):22

PubMed: 25853389

Mol Cancer Ther, 2014, 13(12):2784-92

PubMed: 25319394
Br J Haematol, 2015, 168(3):371-83

PubMed:

Epigenetics, 2015, 10.1080/15592294.2015.1039216

PubMed: 25923331

J Mol Biol, 2014, 426(20):3442-53

PubMed: 24657767

J Neurochem, 2012, 123 Suppl 2:108-15

PubMed: 23050648

Hum Gene Ther, 2014, 25(7):599-608

PubMed: 24568341

Biochemical Pharmacology, 2015, 94(2):79-90

PubMed:

Biochemical Pharmacology, 2015, 94(2):79-90

PubMed:

J Leukoc Biol, 2012, 91(5):701-9

PubMed: 22028329

J Transl Med, 2011, 9:37

PubMed: 21477288

J Biol Chem, 2015, 290(8):5028-40

PubMed:

J Biol Chem, 2014, 289(14):9918-25

PubMed: 24515107

J Biol Chem, 2013, 288(35):25593-602

PubMed: 23878197
J Biol Chem, 2013, 288(20):14400-7

PubMed: 23539624

J Biol Chem, 2012, 287(43):36609

PubMed: 22952229

Cancer Cell Int, 2014, 10.1186/s12935-014-0112-x

PubMed:

Mol Carcinog, 2013, 52(3):218-28

PubMed: 22121107

Mol Carcinog, 2012, 52(6):459-74

PubMed: 22308110

Mol Cell Biol, 2014, 34(7):1280-9

PubMed: 24469401

J Pharmacol Exp Ther, 2010, 86(16):8765-72

PubMed: 20739454

Proteomics Clin Appl, 2014, 8(11-12):924-31

PubMed: 25091122

Invest New Drugs, 2012, 30(2):541-7

PubMed: 21107885

Genes Brain Behav, 2013, 13(1):69-86

PubMed: 24286462

J Alzheimers Dis, 2014, 41(4):1193-205

PubMed: 24844691

Retrovirology, 2011, 2(3):411-23

PubMed: 21966324
Cancer Biol Ther, 2014, 15(5):578-85

PubMed: 24556916

Pharm Res, 2012, 29(7):1960-76

PubMed: 22415140

BMC Cancer, 2015, 15(1):273

PubMed: 25880212

BMC Cancer, 2014, 14(1):373

PubMed: 24886166

FEBS Lett, 2015, 589(10):1080-8

PubMed: 25816750

FEBS Lett, 2014, 588(9):1571-9

PubMed: 24607544

J Hum Genet, 2016, 10.1038/jhg.2016.61

PubMed: 27251006

J Hum Genet, 2016, 10.1038/jhg.2016.61

PubMed: 27251006

PLoS One, 2013, 8(1):e53766

PubMed: 23320102

PLoS One, 2012, 7(9):e44265

PubMed: 22957056

PLoS One, 2012, 7(12):e52335

PubMed: 23272238

PLoS One, 2012, 7(12):e52753

PubMed: 23300762
PLoS One, 2011, 6(7):e22739

PubMed: 21818379

Chronobiol Int, 2012, 29(8):982-93

PubMed: 22891617

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086

Exp Dermatol, 2010, 19(12):1096-102

PubMed: 20629733

Biochem Biophys Res Co, 2012, 420(2):325-30

PubMed: 22425986

J Biotechnol, 2015, 10.1016/j.jbiotec.2015.02.029

PubMed: 25746901

BMC Neurosci, 2011, 12:50

PubMed: 21615950

Mol Med Rep, 2014, 10(5):2729-35

PubMed: 25199623

Pediatr Surg Int, 2012, 28(6):579-89

PubMed: 22526548

Protein Expr Purif, 2012, 86(1):45-52

PubMed: 21992606

Oncotarget, 2017, 10.18632/oncotarget.15017

PubMed: 28157715

Head Neck, 2014, 10.1002/hed.23822.

PubMed: 24986420
Cytometry A, 2014, 85(1):78-87

PubMed: 24038859

Curr Pharm Desigh, 2014, 20(11):1874-80

PubMed: 23888956

Pharmacology Research Perspectives, 2014, 10.1002/prp2.43

PubMed:

Oncotarget, 2014, 5(15):5965-77

PubMed: 25115389

20 Customer Reviews

Activity of vorinostat in Jurkat and Peer T-ALL cell lines in an MTT cell viability assay. Cells were treated with increasing drug concentrations for 72 h. The data are plotted as the mean % of DMSO-treated control cells against the corresponding drug concentration. The error bars are the standard error. For each drug and cell line, 3-4 independent experiments were performed with 6 replicates at each drug concentration.

Nature 2011 471, 235-9. Vorinostat (SAHA, MK0683) purchased from Selleck.

Differential effects of HDAC inhibitors on histone and tubulin acetylation. Immunofluorescence analysis of histone H3 (K9ac/K14ac) and tubulin acetylation in HeLa cells treated for 4 h with vehicle, SAHA (10 μM), tacedinaline (50 μM), PCI-24781 (20 μM. (a) Mapping of histone acetylation in K562 cells treated with HDAC inhibitors by LC-MS/MS. Cells were treated with TSA (10 μM), SAHA (5 μM), PCI-24781 (2 μM), tacedinaline (50 μM) for 6 h. Histones were extracted from cells and acetylated peptides were quantified after isobaric tagging.

Nat Biotechnol 2011 29, 255-265. Vorinostat (SAHA, MK0683) purchased from Selleck.
Western blot analysis of histone H3 acetylation in the spleen of untreated and vorinostat-treated hNF-E2 tg mice (n = 4 of each genotype).

J Exp Med 2012 209, 35-50. Vorinostat (SAHA, MK0683) purchased from Selleck.

SAHA down-regulates c-FLIP expression and increases the sensitivity of CaP cells to undergo apoptosis in the presence of bicalutamide (A) Bar graph illustrating the sub-G0/G1 cell population in 22Rv1 (left panel) and LNCaP (right panel) cells in the absence and presence of 10μM bicalutamide, administered as a single agent or in ombination with increasing concentrations of the HDAC inhibitor, SAHA. (B) Immunoblots demonstrating the single agent activity of bicalutamide or SAHA, or effect upon their combined administration on the expression of c-FLIP and/or the processing of PARP. Equal protein loading was confirmed by GAPDH. (C) Bar graph illustrating the effect of bicalutamide and SAHA upon the induction of caspase-8 or caspase-3/7 activity in 22Rv1 cells (left panel) and LNCaP cells (right panel). (D) Immunoblots characterizing the impact of SAHA and/or bicalutamide upon the induction of PARP cleavage, in the absence or presence of the pan-caspase inhibitor, ZIETD. ZIETD was incubated with the cells for 12 h prior to the experiment. All data points shown in (A) and (C) represent the mean ± S.E.M. value, calculated from four independent experiments.

Clin Cancer Res 2012 18, 3822-33. Vorinostat (SAHA, MK0683) purchased from Selleck.
Analyses of efficacy, potency and IC50 of HDAC inhibitors point toward HDACs 1–3 as relevant candidates for beta cell protection. Ranking and raw data on ITF drugs (Table 3) and commercial HDAC inhibitors (Table 4) underlying the heat maps of Fig. 1 (A and B). The HDAC inhibitor compounds were tested using a HDAC activity kit and recombinant proteins to determine IC50 values on each individual HDAC (right part of the table). Each drug was further tested using Real-Time Cell Analysis (RTCA) to score their maximal effective concentration (ECmax) as well as the corresponding rescue percentage of cytokine treated INS-1 cells. The drugs were ranked according to % rescue. * DMSO alone controls were included in each experiment, but not shown here. The results indicate that the highest concentrations of DMSO used here (1:1,000) were slightly potentiating the proliferation of the cells. The effects observed in this group of compounds were ascribed to the DMSO.?

Diabetologia 2012 55, 2421-2431. Vorinostat (SAHA, MK0683) purchased from Selleck.

Suberoylanilide hydroxyamic acid (SAHA) preserves CFP (+) expression in mouse optic nerves (MONs) from older mice. (a) CFP (+) mitochondria were longer and thicker in MONs from 12-month-old Thy-1 CFP mice (inset; scale bar = 2 μm). Oxygen–glucose deprivation (OGD) consistently reduced CFP pixel intensity in 12-month-old MONs despite longer and brighter CFP ( +) mitochondria (yellow arrows). (b) Blockade of AMPA/kain ate receptors with NBQX (30 μM), or pan-Histone deacetylase (HDAC) inhibition with SAHA (5 μM), effectively preserved CFP pixel intensity during OGD. The preservation of CFP (+) mitochondria correlates with protection of the CAP area during OGD and profound recovery.

J Neurochem 2012 123 Suppl 2, 108-15. Vorinostat (SAHA, MK0683) purchased from Selleck.
D and E, Regression of IL-13Ra 2-negative pancreatic tumors treated with SAHA and/or IL-13-PE. Mice were treated daily with i.p. injection of SAHA (25 mg/kg) from day 4 after tumor implantation for two weeks followed by i.t. injection of IL-13-PE (100 μ g/kg) from day 5 for two weeks. F and G, Regression of IL-13Ra 2-posotive pancreatic tumors (HS766T and MIA-PaCa2) treated with SAHA and/or IL-13-PE. The schedule of treatment was similar as in panel D and E. Statistical significances are shown by *: P < 0.05,†: P < 0.001.

J Transl Med 2011 9, 37. Vorinostat (SAHA, MK0683) purchased from Selleck.

IL-13Rα2 expression is upregulated in pancreatic tumors but not in organs of mice after treatment with HDAC inhibi tor, SAHA. A, qRT-PCR of human IL-13Rα2 in implanted pancreatic tumors after SAHA and IL-13-PE treatment. Tumors were harvested next day after IL-13-PE treatment and total RNA extracted. Data shown is ratio of human IL-13Rα2/β-actin expression and multiplied by 1000 for convenience. Bars , SD of triplicate determinations. B, qRT-PCR of mouse IL-13Rα2 in mice organs after SAHA and IL-13-PE treatment. Tissues were harvested at the same time point as in panel A and total RNA extracted. Data shown is ratio of mouse IL-13Rα2/β-actin expression and multiplied by 100 for convenience. C, IHC of human IL-13Rα2 in implanted pancreatic tumors after SAHA and IL-13-PE treatment. D, IHC of mouse IL-13Rα2 in mice organs after SAHA and IL-13-PE treatment. Liver, brain, kidney, pancreas, lung and spleen were fixed for immunostaining of mouse IL-13Rα2 as visualized by Alexa555. Nucleus was counterstained by DAPI.

J Transl Med 2011 9, 37. Vorinostat (SAHA, MK0683) purchased from Selleck.
Proliferation o f HT29 and HCT116 cells after 48 h of butyrate or SAHA treatment. Proliferation measurements using the xCEL Ligence RTCA DP instrument (Roche) in cells treated with increasing doses of butyrate or SAHA, compared with control medium cells (0) (*P < 0.05). The mean ?SEM of three cell culture replicates is shown.

Mol Carcinog 2012 52, 459-74. Vorinostat (SAHA, MK0683) purchased from Selleck.

SAHA induces the down-regulation of cFLIP expression and promotes TRAIL-mediated activation of a mitochondrial-operated apoptotic pathway. a BT-474 cells were treated as indicated in Fig. 1 and the cells were then harvested to analyse caspase-8, Bid, caspase-9, caspase-3 and PARP expression, using GAPDH as the protein loading control. b BT-474 cells were treated with SAHA for 8 h at the doses indicated and subsequently, the cells were harvested and the apoptosis-related proteins were analysed in western blots as described in the "Materials and Methods". The results shown are representative of at least three independent experiments

Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck.
Treatment with SAHA sensitizes breast cancer cells to TRAILinduced apoptosis. BT-474 and MDA-MB-231 cells were incubated for 8 h with SAHA at the doses indicated. After this time, TRAIL (500 ng/ml) was added to some of the cultures for an additional 15 h. Apoptosis was measured as the percentage of cells with subG1 DNA content as described in the "Materials and methods". The results show the mean and S.E.M. of three independent experiments

Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck.

SAHA facilitates the Itch/AIP4-independent proteasomal degradation of cFLIP proteins in breast cancer cells. a BT-474 cells were treated with SAHA (5 μM) for 8 h in the presence or absence of the proteasome inhibitors MG132 or epoxomicin (at the doses indicated), and they were then harvested and the cFLIP content was analysed in western blots. b BT-474 cells were transfected with either the siRNA oligonucleotides targeting Itch/AIP4 or the non-targeting RNA oligonucleotide (scrambled) for 48 h as described in the "Materials and Methods". Subsequently, the cells were treated with SAHA (5 μM) for 8 h and then cFLIP and Itch/AIP4 expression was analysed in immunoblots

Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck.
cFLIP down-regulation following SAHA treatment is responsible for the sensitization of breast cancer cells to TRAIL. a BT-474 cells were transfected with either different siRNAs directed against the cFLIP isoforms or the non-targeting RNA oligonucleotide (scrambled) as described in the "Materials and Methods". After 24 h, the cells were treated with TRAIL (500 ng/ml) for a further 15 h and apoptosis was then measured as the percentage of cells with subG1 DNA content. The results show the mean and S.E.M. of three independent experiments. To verify protein knockdown, cells were harvested 24 h after transfection and the cFLIP levels were assessed in immunoblots. b. BT-474 cells overexpressing Cflipl (pBABE-FLIPL) or control cells (pBABE) were treated with SAHA for 8 h at the doses indicated. After this time, TRAIL (500 ng/ml) was added to some cultures for 15 h. Apoptosis was measured as the percentage of cells with subG1 DNA content and the results show the mean and range of two independent experiments. Western blots show the cFLIP levels after SAHA treatment in pBABE and pBABE-FLIPL cells.

Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck.

Vorinostat inhibits the tumor growth. NOD ⁄ SCID-B2m^-/-mice were injected s.c. with 1×10⁶ MyLa2059 cells into both flanks. When the mice had developed established palpable tumors treatment was initiated (day 1). The mice received either vehicle (black line) or 60 mg ⁄ kg vorinostat (grey line) i.p. five days a week. In total, there were four mice in the group receiving vehicle and three mice in the group receiving vorinostat. The length and width of the tumors were measured continuously until the experiment was terminated on day 20 post treatment initiation. The tumor volume was calculated using the formula V = (a×b²)/2, where a defines the length (mm) and b the width (mm) of the tumor. The histogram shows the average tumor volume per flank ± SEM. * denotes a significant difference (P < 0.05) in the average tumor volume per flank between mice treated with vehicle and vorinostat at the given time-point both by using a one-tailed two samples test with Welch^,scorrection and a Mann-Whitney U test.

Exp Dermatol 2010 19, 1096-1102. Vorinostat (SAHA, MK0683) purchased from Selleck.
(a) Western blot of whole cell extracts demonstrates SAHA and NaB treatment result in increased levels of acetylated histone H3 compared to vehicle controls. (b) Light micrographs of HDACi/vehicle treated cultures illustrate the paucity of neurospheres in HDACi-treated cultures. (c) Quantitative analysis confirms SAHA and NaB inhibit the formation of neurospheres (diameter ≥ 50 μm) and increase the prevalence of small cell clusters (≥ 4 cell, diameter < 50 μm). (d) Flow cytometry using LIVE/DEAD cell stain confirms SAHA and NaB are minimally toxic compared to vehicle controls (n = 3). Scale bar = 100 μm.

BMC Neurosci 2011 12, 50. Vorinostat (SAHA, MK0683) purchased from Selleck.

(a) EdU flow cytometry of live cell-gated adult mouse NSCs demonstrates SAHA (**p < 0.01) and NaB (***p < 0.001) significantly inhibit DNA synthesis. (b) Analysis of DNA content by flow cytometry reveals significant accumulation of adult mouse NSCs in G1phase of the cell cycle following SAHA (*p < 0.05) and NaB (*p < 0.05) treatment. (c) Correspondingly the proportion of cells in G2/M phase is significantly reduced following SAHA (*p < 0.05) and NaB (*p < 0.05) treatment. (d) Fluorescence micrographs of HDACi/vehicle treated adult NSCs pulse-labeled with EdU for flow cytometry. Scale bar = 50 μm. Statistical comparisons performed using one-way ANOVA with post hoc Newman-Keuls multiple comparison tests.

BMC Neurosci 2011 12, 50. Vorinostat (SAHA, MK0683) purchased from Selleck.
(a) Immunofluorescence labeling of NeuN, GFAP and Olig2 cell fate markers reveals reduced expression of GFAP (*p < 0.001) and Olig2 (*p < 0.05) in adult mouse NSCs treated with SAHA for 48 hours under proliferation culture conditions and then induced to differentiate for 14 days in culture (two-way ANOVA with Bonferroni post-tests). (b) Western blot of β-catenin protein in nuclear and cytoplasmic fractions of adult mouse NSCs treated with HDACi/vehicle control under proliferation culture conditions. Gapdh and lamin A/C blots are included as loading controls. (c) SAHA and NaB do not significantly alter nuclear/cytoplasmic levels of β-catenin in adult mouse NSCs. Histogram of β-catenin Western blot signal intensities normalized to loading controls (n = 4).

BMC Neurosci 2011 12, 50. Vorinostat (SAHA, MK0683) purchased from Selleck.

Morphological changes and histone H3 phosphorylation of HB cells treated with a combination of VX-680 and SAHA. HUH6 and HepT1 were incubated with VX-680 (6 μM) and SAHA (0.5 μM). Nuclei diameter (a) and cell diameter (b) were determined 72 h later by DAPI staining and microscopy. Data represent mean±SD of the diameters from 20 cells in each experiment. (* Two-way ANOVA, Bonferroni test, p \0.05). c Western blot analysis on HUH6 and HepT1 cells were carried out with an anti-phospho-Histone H3 (Ser 10) antibody (p-H3) 24 h after incubation with VX-680 (10 μM), SAHA (0.2 μM) or a combination of both. Controls were left untreated. Western blot analysis showed a decrease in p–H3 after treatment with VX-680 ( lane 2 ) relative to controls ( lane 1 ) and an increase when SAHA was added ( lane 3 ). For the combination of VX-680 and SAHA (lane 4 ) no p-H3 was detected.

Pediatr Surg Int 2012 28, 579-89. Vorinostat (SAHA, MK0683) purchased from Selleck.
Vorinostat promotes C2C12 differentiation.In the image, the red is the myotube indicating differentiation ,the blue is the nuclei.

Dr. Akihiko Yoshimura of Akihiko Yoshimura. Vorinostat (SAHA, MK0683) purchased from Selleck.

Western blot analysis of Acetyl-H3 and H3. 0-20μM SAHA was added.

Dr. Zhang of Tianjin Medical University. Vorinostat (SAHA, MK0683) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.

Targets

HDAC ^[1]
(Cell-free assay)

~10 nM

In vitro

Vorinostat inhibits the activities of HDAC1 and HDAC3 with IC50 of 10 nM and 20 nM, respectively. Vorinostat also results in a marked hyperacetylation of histone H4. ^[1] Vorinostat inhibits the growth of three prostate cancer cell lines LNCaP, PC-3 and TSU-Pr1 at micromolar concentrations (2.5-7.5 μM), and induces dose-dependent cell death in LNCaP cells. ^[2] Vorinostat treatment in MCF-7 cells inhibits cell proliferation at an IC50 of 0.75 μM resulting in the accumulation of cells in the G1 and G2-M phase of the cell cycle. Vorinostat also induces differentiation in the estrogen receptor-negative cell line SKBr-3 and the retinoblastoma-negative cell line MDA-468. ^[3] Vorinostat treatment at 1 μM for 8 hours or more is sufficient to irreversibly induce apoptosis of human multiple myeloma (MM) cells. The gene expression profiles of Vorinostat treated MM cells are not hallmarked by global transcriptional activation, but by coordinated transcriptional changes of specific functional groups of genes such as cytokine-induced proliferative/survival signaling cascades, oncogenes-tumor suppressor genes, regulators of apoptosis, DNA synthesis-repair and cell cycle, and proteasome-ubiquitin function. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
A20	M2L0PGtqdmG\|ZTDBd5NigQ>?		NVu4XXZkOSCq	MX;EUXNQ	Mn[0ZY51cS2KRFHDNUBi[3Srdnn0fUB4cXSqIFnDOVAhd2ZiMD6xNVIh\|ryP	MYexNVk3ODR6OR?=
Friend leukemic cell	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIO5eXg2OCEQvF2=	Ml;LO\|IhcA>?	Mnm0SG1UVw>?	MVzJR\|UxRTBwOUmg{txO	M3PXflEzOTB7OUGz
K562	NEjmeVJMcW6jc3WgRZN{[Xl?		NVmwXFNxPiCq	NWjzV2lOTE2VTx?=	MXTJcohq[mm2aX;uJI9nKGi3bXHuJIhqe3SxbnWg[IVi[2W2eXzhd4UhMG2reIT1doUhd2ZiSFTBR\|Eh[W6mIFjERWMzMSC5aYToJGlEPTBib3[gNE4xOSEQvF2=	MkjDNVI1OTl\|OEC=
HT1080	NYPwWHNJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEnybG04OiCq	MlzrSG1UVw>?	MojiTWM2OD1{LkSg{txO	M1r5XFEzOjdyMUe1
H1299	MYTLbY5ie2ViQYPzZZk>		MY[yNEBucW5?	MYXEUXNQ	MmDjTY5pcWKrdH;yfUBi[3Srdnn0fUBi\2GrboP0JGhFSUNiZX76fY1mKHerdHigTWM2OCCxZjCwMlE6PCEQvF2=	M2GxXVE1PTJzNEKy
H1299	Mn\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NEO2Xlg4OiCq	MX3EUXNQ	MU\JR\|UxRTdwMkSg{txO	M3ywSlE1PTJzNEKy
HeLa	MmSzT4lv[XOnIFHzd4F6		NHTHc\|U{OCCvaX6=		MYPJcohq[mm2b4L5JINwdmOnboTyZZRqd25iYXfhbY5{fCCqaYP0c45mKGSnYXPleJlt[XOnIIfpeIghUUN3MDDv[kAxNjJ6IN88US=>	NXfWUYJEOTV4MEO5OFk>
LOX-IMVI	M{\Ldmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXuycXlWPDhiaB?=		M{\XSGlEPTB;MT6zJO69VQ>?	NEnYN4EyPTdzNUS3NC=>
NCI-H226	NX\DUmo3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmLmOFghcA>?		M{LxUWlEPTB;Mj62JO69VQ>?	NHm4SYsyPTdzNUS3NC=>
RXF-631L	MlHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Ml7mOFghcA>?		M4fKemlEPTB;MjFOwG0>	MmfUNVU4OTV2N{C=
SNB-78	MkCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{nBcFQ5KGh?		NV;MO4p3UUN3ME2xOkDPxE1?	NFHNU28yPTdzNUS3NC=>
St-4	NGfMWHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NX63bYQ5PDhiaB?=		MmPZTWM2OD13LkKg{txO	M1zsb\|E2PzF3NEew
ARP1	NF34[XpHfW6ldHnvckBCe3OjeR?=	NUX1SHBPOiEQvF2=	NVK2XFZQPiCq		NWHKdmExUW6mdXP0bY9vKG:oIGCyNXdCTjFiZ3Xu[UBmgHC{ZYPzbY9v	NHS1VpYyPDd\|NEiwOi=>
CEM	M2PDVGtqdmG\|ZTDBd5NigQ>?		MUWxJIg>	NXnjSXhCTE2VTx?=	MWfJcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwM{Og{txO	MXSxOlQzODB4NB?=
HCT15	NGi3bXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWK0PEBp		NXjMfIg5T0l3ME2wMlgzKM7:TR?=	MVWxOlczOzJ{Nx?=
NCI-H23	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MkPCOFghcA>?		M1e1V2dKPTB;MD65NkDPxE1?	MmGwNVY4OjN{Mke=
GM15850	MlfJT4lv[XOnIFHzd4F6	MV2yMlUh\|ryP	M4jkTlk3KGh?	MUfEUXNQ	MmP4TY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHjpd5RwdmViSEOgcJl{cW6nIEG0JIFk\XS7bHH0bY9vKG:oIF\YUkBo\W6n	Mmj3NVY6OjF\|Nke=
GM15850	Mn;CT4lv[XOnIFHzd4F6	M3O1XFIvPSEQvF2=	NYjHeIV{QTZiaB?=	MVzEUXNQ	NF;rWlRKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIOEBtgXOrbnWgOUBi[2W2eXzheIlwdiCxZjDGXG4h\2WwZR?=	NHu1eGkyPjl{MUO2Oy=>
GM15850	NHzITHVMcW6jc3WgRZN{[Xl?	NFO3V2ozNjVizszN	NGLSemM6PiCq	NED3b49FVVOR	Mme2TY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHjpd5RwdmViSESgcJl{cW6nIEGyJIFk\XS7bHH0bY9vKG:oIF\YUkBo\W6n	NHXlPGQyPjl{MUO2Oy=>
GM15850	MmjnT4lv[XOnIFHzd4F6	MnfYNk42KM7:TR?=	NXv3S\|NbQTZiaB?=	NH3pVXhFVVOR	MV7Jcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iaHnzeI9v\SCKMzDsfZNqdmViOTDhZ4V1gWyjdHnvckBw\iCIWF6g[4Vv\Q>?	MYqxOlkzOTN4Nx?=
GM15850	M17UUmtqdmG\|ZTDBd5NigQ>?	MoPQNk42KM7:TR?=	MnPMPVYhcA>?	NWnM[3B{TE2VTx?=	NHniNWhKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIOEBtgXOrbnWgPEBi[2W2eXzheIlwdiCxZjDGXG4h\2WwZR?=	NGLDSY0yPjl{MUO2Oy=>
GM15850	M1vFVGtqdmG\|ZTDBd5NigQ>?	Mki2Nk42KM7:TR?=	Ml;oPVYhcA>?	NUjLU5hXTE2VTx?=	MUHJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iaHnzeI9v\SCKNDDsfZNqdmViMU[gZYNmfHmuYYTpc44hd2ZiRmjOJIdmdmV?	MXuxOlkzOTN4Nx?=
U937	M{DrZ2Z2dmO2aX;uJGF{e2G7	NV\LN3BoPSEQvF2=	MXyyOEBp	MYjEUXNQ	NXz1eo9CS2WubDDjfYNt\SCjcoLld5Qh[nliYXPjeY12dGG2aX;uJIF1KFNxR{KvUUBxcGG\|ZR?=	M2KxOVE4ODB2N{G4
H661	NGHOU2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnTOOFghcA>?		NGHVfXpKSzVyPUGg{txO	MkfLNVcyPTdyMEm=
U937	NYW1XItqTnWwY4Tpc44hSXO\|YYm=	NGTqXmk2KM7:TR?=	M4TWelI1KGh?	M{fH[mROW09?	MUPJcoNz\WG\|ZTDpckBpcXO2b37lJGg{KGGlZYT5cIF1cW:w	MofFNVc1PDd5NUC=
U937	M131XGZ2dmO2aX;uJGF{e2G7	NF7P[HEyKM7:TR?=	NEPqbXQzPCCq	MWnEUXNQ	MoTDSYZn\WO2IH;uJIFteGijIIT1ZpVtcW5iYXPleJlt[XSrb36=	NGLnc5gyPzR2N{e1NC=>
RAW264.7	MlzVSpVv[3Srb36gRZN{[Xl?	M1e5VFExKM7:TR?=	MmPvNlRp	MUX3ZZRmeg>?	Ml\QTY5pcWKrdHnvckBw\iCOUGOtd5RqdXWuYYTl[EBVVk[jbIDoZUBxem:mdXP0bY9vKHerdHigTWM2OCCxZjCwMlc3KM7:TR?=	MknyNVc1Pzd3MUi=
RAW264.7	MX3GeY5kfGmxbjDBd5NigQ>?	NWrPZ4xPOTBizszN	NH3TfZQzPGh?	NHrMTIx4[XSnch?=	Ml32TY5pcWKrdHnvckBw\iCOUGOtd5RqdXWuYYTl[EBPVyCycn;keYN1cW:wIIfpeIghUUN3MDDv[kAyNjh6IN88US=>	MmTCNVc1Pzd3MUi=
SC9	M3nXeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUPSZWdRPDhiaB?=		M{K3O2lEPTB;MD62NFYh\|ryP	NIj1T5kyPzVyN{KxPS=>
ST14A	M2HRRmZ2dmO2aX;uJGF{e2G7	MXu1JI5O	MYG3NkBp		MVnJcoNz\WG\|ZTDpckBTTVOWL17SV2YhdVKQQTDlfJBz\XO\|aX;u	MmHFNVc2PjV7OUO=
ST14A	MlW0SpVv[3Srb36gRZN{[Xl?	NGjoWo02KG6P	MVG3NkBp		M4\Mb2lv[3KnYYPlJIlvKEV{RkGgcXJPSSCneIDy[ZN{cW:w	M17TSVE4PTZ3OUmz
PANC1	NFuxWVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M17WfFEh\|ryP			NFfNSZlKSzVyPUCuOFUh\|ryP	M4Hw[lE4PTh6N{S0
PANC1	NFvaNpBHfW6ldHnvckBCe3OjeR?=	M1nZZ\|Eh\|ryP	NGDSUlEzPCCq		MYDJcoNz\WG\|ZTDpckBxOjGZQV[xM2NKWDFiZ3Xu[UBmgHC{ZYPzbY9v	M17qNlE4PTh6N{S0
PANC1	M17YRWZ2dmO2aX;uJGF{e2G7	MmeyNUDPxE1?	MmTQNlQhcA>?		NVLuV3h[UW6lcnXhd4UhcW5icEK3b4lxOSCpZX7lJIV5eHKnc4Ppc44>	NIjOPY0yPzV6OEe0OC=>
PT45	NFHkcJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkHuTWM2OD12IN88US=>	M{nr[\|E4PTh6N{S0
ACHN	M4e0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Ml\FNlEhcA>?		MWfHTVUxRTBwNkWg{txO	Mo\ZNVc3PjJ4ME[=
PC3	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MV6yNUBp		Ml76S2k2OD1yLkexJO69VQ>?	MVmxO\|Y3OjZyNh?=
A431	NF62SnlEgXSxdH;4bYMhSXO\|YYm=		NIj3fI04OiCq		M1OxbmlEPTB;ND6yJO69VQ>?	MV:xO\|Y6OTd4Mx?=
Cal27	MUDDfZRwfG:6aXOgRZN{[Xl?		MWW3NkBp		MmDwTWM2OD1\|LkKg{txO	M4CycVE4PjlzN{[z
CCRF-CEM	NX:zdosxS3m2b4TvfIlkKEG\|c3H5		NFfuVJk4OiCq		NX2xfllXUUN3ME2wMlgh\|ryP	MY[xO\|Y6OTd4Mx?=
EOL1	MWrDfZRwfG:6aXOgRZN{[Xl?		MkDVO\|IhcA>?		NUX4WXlMUUN3ME2xJO69VQ>?	MmrNNVc3QTF5NkO=
Hec-1-A	M37hUGN6fG:2b4jpZ{BCe3OjeR?=		MV23NkBp		MXXJR\|UxRTFizszN	Mo\1NVc3QTF5NkO=
HeLa	M17xSWtqdmG\|ZTDBd5NigQ>?	MoTKNVAh\|ryP	M{jSflMxKG2rbh?=	MUPEUXNQ	M3rVd2lvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgTGRCSzFid3n0bEBKSzVyIH;mJFAvODJizszN	MX6xO\|Y6OTd4Mx?=
RKOp21	NGLrWJpEgXSxdH;4bYMhSXO\|YYm=		NXznNG97PzJiaB?=		M2\4[mlEPTB;MT63OkDPxE1?	MkOwNVc3QTF5NkO=
Saos2	NIXudGxEgXSxdH;4bYMhSXO\|YYm=		MmHCO\|IhcA>?		M17yV2lEPTB;Mj6zJO69VQ>?	NGi1dlcyPzZ7MUe2Ny=>
SK-OV-3	NWDLNJhRS3m2b4TvfIlkKEG\|c3H5		MlTkO\|IhcA>?		M1fzR2lEPTB;Mj6yJO69VQ>?	MmDtNVc3QTF5NkO=
U87MG	NV32ZZBjS3m2b4TvfIlkKEG\|c3H5		M1jzVlczKGh?		NV63OpRsUUN3ME2xNUDPxE1?	Ml\ONVc3QTF5NkO=
NUGC3	NF;yN\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXi1JO69VQ>?	NH3vb5MzPCCq		MU\HTVUxRTJwN{mg{txO	NVnTRXI{OTd7MES4OFM>
CCD1059SK	M1LlfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUDt[I5lUUN3ME20N{42KM7:TR?=	Ml7vNVgzPDd3NUS=
HepG2	NIC0WHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjJR\|UxRTBwMECwOkDPxE1?	NGH6OGcyQDJ2N{W1OC=>
HT1080	NY\GV2t1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXXJR\|UxRTBwMECyOEDPxE1?	NH7jS\|UyQDJ2N{W1OC=>
SKBR3	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2G3TWlEPTB;MD64JO69VQ>?	M2PvclE5OjR5NUW0
SNB78	NH\3NFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGr4bZRGSzVyPUG2JO69VQ>?	MX:xPFI1PzV3NB?=
SQ20B	M3vTbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlzqTWM2OD1\|IN88US=>	Ml\TNVgzPDd3NUS=
St4	NUj0XXdyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{TpPGVEPTB;NT6yJO69VQ>?	M3TXdVE5OjR5NUW0
MCF7	M4WzRWZ2dmO2aX;uJGF{e2G7	NWK3dlZsOTBizszN	MmGxPEBp	NWqwWmhvTE2VTx?=	NUi4eoR4UW6mdXP0bY9vKG:oIIT1ZpVtcW5iaInw[ZJi[2W2eXzheIlwdg>?	NVXBR\|hwOTh{NkmyNlY>
HEK293	MX\LbY5ie2ViQYPzZZk>		NHjEb3oyKGh?	NGq2O\|VFVVOR	NW\1Sm9KUW6qaXLpeIlwdiCxZjDISGFEOSC5aYToJGlEPTBib3[gNE4xOyEQvF2=	MnfTNVg{ODh3NkO=
HEK293	NFj2UGpMcW6jc3WgRZN{[Xl?		NHfFWIgyKGh?	NIPCXpJFVVOR	NUXx[XZ3UW6qaXLpeIlwdiCxZjDISGFEOyC5aYToJGlEPTBib3[gNE4xPTdizszN	MmrKNVg{ODh3NkO=
G401	Ml:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVS5R5p7PzJiaB?=	NF\YU21FVVOR	NWLvWoN5UUN3ME2xJO69VQ>?	NF7IeYMyQDN5MEO3Ny=>
HeLa	M{PGZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUC3NkBp	M3TnNmROW09?	NUXIRXgzUUN3ME2wMlQ3KM7:TR?=	MkXuNVg{PzB\|N{O=
Human renal epithelial cell	NGrpd4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2W1OFczKGh?	MYnEUXNQ	NXHr[lNJUUN3ME2xOEDPxE1?	NFH1dlQyQDN5MEO3Ny=>
U937	MWHGeY5kfGmxbjDBd5NigQ>?	M4f6S\|Uh\|ryP	MknZNlQhcA>?		MW\JcoR2[3Srb36gc4YhcGm\|dH;u[UBJPCCqeYDldoFk\XS7bHH0bY9v	NFzSNmQyQDN6MUKzPC=>
U937	Mm\RSpVv[3Srb36gRZN{[Xl?	NVfqcIlUPSEQvF2=	MUiyOEBp		NXf0O2tJUW6mdXP0bY9vKG:oIHHsdIhiKHS3YoXsbY4hcHmyZYLhZ4V1gWyjdHnvci=>	MlSwNVg{QDF{M{i=
U937	NUHadoZITnWwY4Tpc44hSXO\|YYm=	M4Xzd\|Uh\|ryP	MWmyOEBp		M2HNfmlv\HWldHnvckBw\iCyMkGg[ZhxemW\|c3nvci=>	MmL4NVg{QDF{M{i=
U937	NHPy[XhHfW6ldHnvckBCe3OjeR?=	M2\hbVUh\|ryP	M33aN\|I1KGh?		NUH3ZXpnUW6mdXP0bY9vKG:oIHHwc5B1d3Orcx?=	NI[1PWUyQDN6MUKzPC=>
U937	M1[1dmZ2dmO2aX;uJGF{e2G7	MojDOUDPxE1?	MWGyOEBp		MXPJcoR2[3Srb36gc4Yh\3KjboXsc4N6fGmlIHTp[oZmemWwdHnheIlwdg>?	MYmxPFM5OTJ\|OB?=
U937	MUTLbY5ie2ViQYPzZZk>	NFjqfZI2KM7:TR?=	Mln5NlQhcA>?		NYTBdpR6UW6qaXLpeIlwdiCxZjDoeY1idiCKRFHDNS=>	MkDtNVg{QDF{M{i=
U937	NWLtdlJHU2mwYYPlJGF{e2G7	MkDTOUDPxE1?	NFXKcIszPCCq		NVXJOXJMUW6qaXLpeIlwdiCxZjDoeY1idiCKRFHDOC=>	MXOxPFM5OTJ\|OB?=
HEK-TE	MlT1SpVv[3Srb36gRZN{[Xl?	NGWxd2Q2KM7:TR?=	NV;1dYRLPmh?	MXPEUXNQ	M2m1fmlv[3KnYYPlJIlvKGirc4TvcoUhUDNiYXPleJlt[XSrb36=	NWftVFR4OTh2M{SxOFQ>
HPDE6c7	M1m4cWN6fG:2b4jpZ{BCe3OjeR?=	MUi1NEDPxE1?	NF;2cVY4OiCq	Mnq0SG1UVw>?	M1G2dmlEPTB;MT6zJO69VQ>?	MlHCNVg1QTR2NkO=
Human microvascular epithelial cell	NGfEfWVEgXSxdH;4bYMhSXO\|YYm=	M3jpdlUxKM7:TR?=	MkfRO\|IhcA>?	MV3EUXNQ	MX;JR\|UxRTFwMzFOwG0>	MoPBNVg1QTR2NkO=
Hup T3	M3TQXGN6fG:2b4jpZ{BCe3OjeR?=	MlzUOVAh\|ryP	MV23Nog>	NH\Fb45FVVOR	NWG4RYZOUUN3ME2wMlgh\|ryP	MkOzNVg1QTR2NkO=
Mia Paca2	MmPnR5l1d3SxeHnjJGF{e2G7	M3XaOVUxKM7:TR?=	MofSO\|Jp	Mm\wSG1UVw>?	M{ewU2lEPTB;MT6xJO69VQ>?	NXHpRZdIOTh2OUS0OlM>
Panc 04.03	MYXDfZRwfG:6aXOgRZN{[Xl?	M{LSdVUxKM7:TR?=	NX;nWmpJPzKq	M2[5S2ROW09?	M2HKbmlEPTB;MT6yJO69VQ>?	Mnu4NVg1QTR2NkO=
SU 86.86	M4[5RWN6fG:2b4jpZ{BCe3OjeR?=	NGq5Spg2OCEQvF2=	MVO3Nog>	NIXjPIpFVVOR	MlzWTWM2OD1zLkOg{txO	MVixPFQ6PDR4Mx?=
HEK293	NEfkVHlMcW6jc3WgRZN{[Xl?		MWCzJIg>		NYLQS2FNUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBJTEGFNjDlfJBz\XO\|aX;uJJdqfGhiSVO1NEBw\iByLkCxPUDPxE1?	NV3k[lhlOTh3NUi2Olk>
HeLa	M2nONmtqdmG\|ZTDBd5NigQ>?		M1T2NVIhcA>?		NHLmcYFKdmirYnn0bY9vKG:oIH71Z4xm[XJiSFTBR{B4cXSqIFnDOVAhd2ZiMD6wPFMh\|ryP	MmfvNVg2PTh4Nkm=
RAW264.7	MUfGeY5kfGmxbjDBd5NigQ>?	NFzlTogzKM7:TR?=	NF3sZ3I{NjViaB?=	MYfEUXNQ	NVf1PYs{SW62aX3hcIFzcWGuIHHjeIl3cXS7IHHnZYlve3RiUHzhd41w\Gm3bTDmZYxkcXCjcoXtJIlv\mWldHXkJJdqfGhiSVO1NEBw\iByLkGxJO69VQ>?	MlT1NVg3PDR7Nkm=
NB4			NUG1N2tWPDiq	MlvDSG1UVw>?	M3S1SWlEPTB;MD62JO69VQ>?	MVixPFczOzN2OR?=
HEK293	MX\GeY5kfGmxbjDBd5NigQ>?	Ml3xNVAh\|ryP	Mnn1NlQhcA>?	NH3kSFlFVVOR	NIjRRpRC[3SrdnH0bY9vKG:oIH3veZNmKFewdEPhJJNq\26jbHnu[{BmgHC{ZYPz[YQ>	MUmxPVAzOjZ5NR?=
HCT116	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmHXO\|Jp	NX7pTI1lTE2VTx?=	MWHJR\|UxRTBwM{Gg{txO	MnTONVkxQDR{OUS=
HeLa	M1qxNWtqdmG\|ZTDBd5NigQ>?	MUGyJO69VQ>?	MlrFN\|AhdWmw	MYnEUXNQ	MXfJcohq[mm2aX;uJI9nKEiGQVOyJIlvKGi3bXHuJGhmVGFiY3XscJMhf2m2aDDJR\|UxKG:oIECuNUDPxE1?	Mnr3NVkxQDR{OUS=
IGROV1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWnnSGtoPzJiaB?=	NH;rbFhFVVOR	NHXGO4NKSzVyPUKuNkDPxE1?	MX[xPVA5PDJ7NB?=
IGROV1	M{fl[2tqdmG\|ZTDBd5NigQ>?	NIT2fXo2KM7:TR?=	NYPTNWg{OjRiaB?=	NIrEeY5FVVOR	NYH2d5BRUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IIC1N{Bi[2W2eXzheIlwdg>?	NXziPFk2OTlyOESyPVQ>
IGROV1	MWrLbY5ie2ViQYPzZZk>	MXKxNEDPxE1?	MkD4OEBp	MmXZSG1UVw>?	NVnXOItiUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHjpd5RwdmVvSESgZYNmfHmuYYTpc44>	M3Lo[\|E6ODh2Mkm0
IGROV1	NX3rcGIxU2mwYYPlJGF{e2G7	NI\FNGkyOCEQvF2=	M4LHO\|QhcA>?	MmPHSG1UVw>?	MknMTY5pcWKrdHnvckBw\iCKRFHDOkBie3Onc4Pl[EBieyCjbIDoZU11fWK3bHnuJIFk\XS7bHH0bY9v	Mn\2NVkxQDR{OUS=
T24	NFHKc5dMcW6jc3WgRZN{[Xl?		MkDaN{Bp		M2nnUWlv\HWldHnvckBw\iCqaYP0c45mKEh\|IHHj[ZR6dGG2aX;uJJdqfGhiRVO1NEBw\iByLkGyJO69VQ>?	MUexPVA5PDN7NR?=
T24	MnTWT4lv[XOnIFHzd4F6		M4H1cVMhcA>?		NYXk[mVSUW6mdXP0bY9vKG:oIHHsdIhiKHS3YoXsbY4h[WOndInsZZRqd25id3n0bEBGSzVyIH;mJFAvOjVizszN	MVqxPVA5PDN7NR?=
HeLa	NVPtOWVlU2mwYYPlJGF{e2G7		MoDKNVUhdWmw	MVTEUXNQ	NGjx[2VKdmirYnn0bY9vKG:oIFjERWM3KG[{b32gcpVkdGWjcjDlfJRz[WO2IIfpeIghUUN3MDDv[kAxNjB6NUWg{txO	MYexPVA6Ozh6NB?=
HeLa	NE\jUHVMcW6jc3WgRZN{[Xl?		MlrWNVUhdWmw	M1LQfWROW09?	MUTJcohq[mm2aX;uJI9nKEiGQVO4JIZzd21iboXjcIVieiCneITyZYN1KHerdHigTWM2OCCxZjCxMlg3KM7:TR?=	NIXMOHAyQTB7M{i4OC=>
NCI-H69	NV\MNGpQS3m2b4TvfIlkKEG\|c3H5		MVq3NkBp	M4fvXWROW09?	NWrvZ3p2UUN3ME2yMlA3KM7:TR?=	NGj2b2MyQTB7M{i4OC=>
SKMES1	NFPyXmlEgXSxdH;4bYMhSXO\|YYm=		NILUXJg4OiCq	MYHEUXNQ	MXzJR\|UxRTJwNEKg{txO	M{\nW\|E6ODl\|OEi0
S2	NYPjUGNzU2mwYYPlJGF{e2G7	NF3C[\|AxNjFvMUCg{txO	M3P2OFEhcA>?		M37teWlvcGmkaYTpc44hd2ZiUHzhd41w\Gm3bTDmZYxkcXCjcoXtJGhFSUNzIHX4dJJme3OnZDD3bZRpKEmFNUCgc4YhOC5yNUmg{txO	M3XSZlE6OzF5NEWw
SHSY5Y	NV3tS4hOU2mwYYPlJGF{e2G7	MX[xNEDPxE1?	NGLtW\|g1QCCq	M4G2cGROW09?	MoTlTY5pcWKrdHnvckBw\iCKRFHDJJdqfGhiSVO1NEBw\iByLkWg{txO	MlS3NVk{PDRzN{W=
SHSY5Y	M3rGSWN6fG:2b4jpZ{BCe3OjeR?=	NHz1N3AyOCEQvF2=	NYTFS4lPPDhiaB?=	NHu2SGJFVVOR	M{TTbWlEPTB;MjFOwG0>	NHzM[FgyQTN2NEG3OS=>
DMS114	NVm4OYFKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Ml3ROFghcA>?		MojYS2k2OD1{Lkmg{txO	M1TSO\|E6PDF7MkC1
HBC5	M1\0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3S4R\|Q5KGh?		MWfHTVUxRTF5IN88US=>	Ml3WNVk1OTl{MEW=
SNB78	M3nxTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGTiZ4k1QCCq		Mke2S2k2OD1zNjFOwG0>	MmDiNVk1OTl{MEW=
HeLa	NXjXVVRPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXP4WZlTPzJiaB?=	M2rmXGROW09?	Ml3uTWM2OD1yLkS2JO69VQ>?	M3S3c\|E6PDRzOES2
BHK	MVHLbY5ie2ViQYPzZZk>	MWK1JO69VQ>?	MnHiNlQhcA>?	NV22Npo5TE2VTx?=	M4T6UmlvcGmkaYTpc44hd2ZiSFTBR\|ch\XiycnXzd4VlKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJJBt[XOvYTDt[Y1jemGwZTDG[IVtfGF3MEigR2ZVWiCycn;0[Ylv	MkTLNVk6PjZ5OEm=
CFBE41o-	NEHIOYpMcW6jc3WgRZN{[Xl?	NIPzemY2KM7:TR?=	NF;oN5o5KGh?	NGTo[GZFVVOR	NF\VSJlKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaInw[ZJi[2W2eXzheIlwdiCxZjDobZN1d26nIFiz	MVGxPVk3Pjd6OR?=
CFBE41o-	MofBT4lv[XOnIFHzd4F6	MU[1JO69VQ>?	MU[0JIg>	M3:0WWROW09?	NUK4Z3BlUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJI12fGGwdDDG[IVtfGF3MEigR2ZVWiCycn;0[YlvKGyndnXs	NY\ob4c4OTl7Nk[3PFk>
CFBE41o-	MmDyT4lv[XOnIFHzd4F6	MYKxJO69VQ>?	MYexJIg>	NFvKSWNFVVOR	M1v2TmlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDDSnRTKHC{b4TlbY4hdGW4ZXy=	MnnvNVk6PjZ5OEm=
Primary bronchial epithelial cell	NXrL[WtXU2mwYYPlJGF{e2G7	NFPGSmYyKM7:TR?=	NWjVZ49lOjRiaB?=	MkXBSG1UVw>?	NEj6V\|RKdmirYnn0bY9vKG:oIFjERWM4KGG\|c3Xzd4VlKGG\|IHnu[JVkfGmxbjDv[kBufXSjboSgSoRmdHSjNUC4JGNHXFJicILveIVqdiCjcHnjZYwhe3W{ZnHj[UBtd2OjbHn6ZZRqd25?	NVPKb2xzOTl7Nk[3PFk>
CFBE41o-	MkfWT4lv[XOnIFHzd4F6	NYribWZuOSEQvF2=	NEXE[mI2KGSjeYO=	NXjU[41FTE2VTx?=	NUD1TZZ5UW6qaXLpeIlwdiCxZjDISGFEPyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckB{fGGkaXzpfoF1cW:wIH;mJGZl\Wy2YUWwPEBETlSUIIDyc5RmcW5?	NI\adWwyQTl4Nke4PS=>
CFBE41o-	NYT3[olQU2mwYYPlJGF{e2G7	MU[xJO69VQ>?	NXS2PW9GOjRiaB?=	NF7qZ5JFVVOR	NIeze2dKdmirYnn0bY9vKG:oIFjERWM4KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJGZl\Wy2YUWwPEBETlSUIIDyc5RmcW5idILh[oZq[2urbne=	M4XwWVE6QTZ4N{i5
CFBE41o-	NW\qPHVsU2mwYYPlJGF{e2G7	NFnseGQ2KM7:TR?=	M3z5UlI1KGh?	NHzk[o5FVVOR	MXLJcohq[mm2aX;uJI9nKEiGQVO3JIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIILheIUhd2ZibXH0eZJifGmxbjDv[kBETlSUIIDyc5RmcW5idH:gbZR{KGeueXPv[o9zdQ>?	M1HrWVE6QTZ4N{i5
CFBE41o-	MXLLbY5ie2ViQYPzZZk>	MXy1JO69VQ>?	MWGyOEBp	MkfTSG1UVw>?	M2LYOmlvcGmkaYTpc44hd2ZiSFTBR\|ch[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gd5Ri[mmuaYT5JI9nKE[mZXz0ZVUxQCCFRmTSJJBzd3SnaX6=	NUjtWo1bOTl7Nk[3PFk>
CFBE41o-	M4LLWWtqdmG\|ZTDBd5NigQ>?	MV21JO69VQ>?	NEPHUlAzPCCq	NV7qdpBWTE2VTx?=	NIfQVYNKdmirYnn0bY9vKG:oIFjERWM4KGG\|c3Xzd4VlKGG\|IHPvdpJm[3Srb36gc4YhdXW2YX70JGZl\Wy2YUWwPEBETlSUIITyZYZncWOtaX7nJJRwKGOnbHygd5Vz\mGlZTDhd{BodHmlb3\vdo0>	NUe5dZRrOTl7Nk[3PFk>
Primary bronchial epithelial cell	NUPhNmZJU2mwYYPlJGF{e2G7	Mm[5OUDPxE1?	MoLBNlQhcA>?	NH\2OWVFVVOR	MXHJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6mdXP0bY9vKG:oIH31eIFvfCCIZHXseIE2ODhiQ1\UVkBxem:2ZXnuJIFxcWOjbDDzeZJn[WOnIHzvZ4FtcXqjdHnvci=>	MkfBNVk6PjZ5OEm=
Primary bronchial epithelial cell	MX\LbY5ie2ViQYPzZZk>	NFLnUZcyKM7:TR?=	MoLSPVYhcA>?	NG\WZmlFVVOR	MVLJcohq[mm2aX;uJI9nKEiGQVO3JIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIIPoc5J1KGOrcnP1bZQh[3W{cnXueJM>	MnvRNVk6PjZ5OEm=
BxPC3	M1vidWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NEm5VJE4OiCq		M{T0fmlEPTB;Mj63JO69VQ>?	NWnhfJg4OjBzNEO3O\|g>
CAL27	MnmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MoPJO\|IhcA>?		NGjLO4hKSzVyPUOuO\|Ih\|ryP	NILUbnQzODF2M{e3PC=>
Capan1	Moq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Ml2wO\|IhcA>?		MX\JR\|UxRTdwMzFOwG0>	MXyyNFE1Ozd5OB?=
HCC827	MlTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYe3NkBp		Ml\zTWM2OD1zLkig{txO	NWXiW\|EyOjBzNEO3O\|g>
LNCAP	M1fkeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NETj[3E4OiCq		NFOzNIRKSzVyPUCuOVgh\|ryP	Mo\SNlAyPDN5N{i=
NCI-H2122	NHnIUZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVu3NkBp		NW\FdXdNUUN3ME23MlUh\|ryP	M4fZUFIxOTR\|N{e4
NCI-H358	NFLTSJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnPvO\|IhcA>?		MlK3TWM2OD1{LkWg{txO	M3LYd\|IxOTR\|N{e4
SCC15	NWG4UXN6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVjhcZFqPzJiaB?=		NUf4fFBEUUN3ME2yMlQ6KM7:TR?=	NVLhdmZzOjBzNEO3O\|g>
SCC25	NV\TcVdYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmjNO\|IhcA>?		MUnJR\|UxRTFwOUOg{txO	NFO2XJUzODF2M{e3PC=>
SKHEP1	NXu0S3JbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWPscpRxPzJiaB?=		M{jsXWlEPTB;Mz60OkDPxE1?	M3f3cFIxOTR\|N{e4
BJ	MnL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUjH[4p1OTByIN88US=>	NYXFb\|JRPDhiaB?=	NVr2cYFVTE2VTx?=	NEHwZpJIem:5dHigbY5pcWKrdHnvckBifCByLkC1JJRwKDFyMDD1US=>	Mn;hNlAyPDN6NEC=
MUF	M2jTZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWfrOXdYOTByIN88US=>	NHLP[3U1QCCq	Mo\WSG1UVw>?	NHTjR5lIem:5dHigbY5pcWKrdHnvckBifCByLkC1JJRwKDFyMDD1US=>	M{jNPFIxOTR\|OESw
Caco-2	M1nNN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFjDZY0yODBizszN	M1HSW\|Q5cA>?	MWXEUXNQ	MVzJR\|UxRThwMTFOwG0>	Mn;zNlAyPDN6NEC=
Caco-2	MkH1T4lv[XOnIFHzd4F6	MmjnOUDPxE1?	MoHSOEBp	MmS0SG1UVw>?	M3XTVmlv\HWldHnvckBw\iCKRFHDMY1m\GmjdHXkJIhqe3SxbnWgZYNmfHmuYYTpc44hUUN3MDDv[kAxNjB\|NzFOwG0>	NX\YcWpROjBzNEO4OFA>
Caco-2	NInVPYJMcW6jc3WgRZN{[Xl?	NYrIdGltOC5\|MU[gcm0hfG9iM{GuOkDPxE1?	Mor6OEBp	NV;nfGhRTE2VTx?=	NXT0XY0{TXhidnn2c{BqdmirYnn0bY9vKG:oIHj1cYFvKEiGQVOxJJdqfGhiSVO1NEBw\iByLkGxPUDPxE1?	MWWyNFE1Ozh2MB?=
Caco-2	Mln3T4lv[XOnIFHzd4F6	NYDCfGF5OC5\|MU[gcm0hfG9iM{GuOkDPxE1?	NUXzdZBUPCCq	M13ZUWROW09?	NX;mVmhMTXhidnn2c{BqdmirYnn0bY9vKG:oIHj1cYFvKEiGQVOzJJdqfGhiSVO1NEBw\iByLkG0O{DPxE1?	M2nDR\|IxOTR\|OESw
Caco-2	MWTLbY5ie2ViQYPzZZk>	NV\iZpdEPi5\|MjDuUUB1dyB4M{Kg{txO	NGP2b5Y1KGh?	NUniSW5UTE2VTx?=	NXrQT3NvTXhidnn2c{BqdmirYnn0bY9vKG:oIHj1cYFvKEiGQVO1JJdqfGhiSVO1NEBw\iBzMj62JO69VQ>?	NYfqPHh[OjBzNEO4OFA>
Caco-2	NYHTSoRiU2mwYYPlJGF{e2G7	MmnoOk4{OiCwTTD0c{A3OzJizszN	NHvRUWo1KGh?	MUDEUXNQ	MYrFfEB3cX[xIHnubIljcXSrb36gc4YhcHWvYX6gTGRCSzdid3n0bEBKSzVyIH;mJFQyKM7:TR?=	NEnNfIQzODF2M{i0NC=>
Caco-2	MWnLbY5ie2ViQYPzZZk>	M4LDWVAvOzF4IH7NJJRwKDNzLk[g{txO	MlPkOEBp	MmnWSG1UVw>?	M3T1eGV5KH[rdn:gbY5pcWKrdHnvckBw\iCqdX3hckBJTEGFNh?=	NV\nPWxNOjBzNEO4OFA>
HepG2	MULLbY5ie2ViQYPzZZk>	NE\peY42KM7:TR?=	MV[2bC=>	MX7EUXNQ	MUnJcoR2[3Srb36gc4YhUESDQz3t[YRq[XSnZDDobZN1d26nIHHj[ZR6dGG2aX;u	MVGyNFE1Ozh2MB?=
HepG2	MVjLbY5ie2ViQYPzZZk>	M2XuOVUh\|ryP	Mn;UOog>	MULEUXNQ	NXPyd\|NrUW6mdXP0bY9vKG:oIFjERWMudWWmaXH0[YQhcGm\|dH;u[UBpgXCncnHj[ZR6dGG2aX;u	MYWyNFE1Ozh2MB?=
HepG2	NIXobVBMcW6jc3WgRZN{[Xl?	M2\2e\|Uh\|ryP	MYG2bC=>	Mn;PSG1UVw>?	MU\JcoR2[3Srb36gc4YhUESDQz3t[YRq[XSnZDDhcJBp[S22dXL1cIlvKGGlZYT5cIF1cW:w	M3[4W\|IxOTR\|OESw
HepG2	MUjLbY5ie2ViQYPzZZk>	NHvKOVQ2KM7:TR?=	NYLrNmNNPmh?	MmnCSG1UVw>?	M1PoVGlv\HWldHnvckBw\iCKRFHDMY1m\GmjdHXkJGg{N0h2IHjpd5RwdmViYXPleJlt[XSrb36=	MnO4NlAyPDN6NEC=
COLO205	NGH4VlJMcW6jc3WgRZN{[Xl?	NVnkPWZSOTBizszN	MV6yOEBp	MWDEUXNQ	NYXFZ3dtUW6qaXLpeIlwdiCxZjDISGFEOSCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhcGm\|dH;u[UBJOyCjY3X0fYxifGmxbjD3bZRpKEmFNUCgc4YhOi5{IN88US=>	M2LEZ\|IxPDVzM{e4
SCC4	M3WzdmtqdmG\|ZTDBd5NigQ>?	NYTUUG5vOSEQvF2=	NFT5dlUzPGh?		Mm\KTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIIT1ZpVtcW5iYXPleJlt[XSrb36=	MkPBNlA1PTJ{MkW=
SCC4	MnvjT4lv[XOnIFHzd4F6	MmeyNUDPxE1?	MnP2NlRp		NXvQ[GVHUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgZYNmfHmuYYTpc44>	NIK3clMzODR3MkKyOS=>
SCC4	M4L2bWZ2dmO2aX;uJGF{e2G7	NX7jNHdUOSEQvF2=	M1PhN\|UhdWmw		NWfzS5ljSWexbnnzeEBi[3Srdnn0fUBifCCYRGKgZZN{\XO\|ZXSgZZMhcW6mdXP0bY9vKG:oIFPZVFI1KGenbnWg[ZhxemW\|c3nvci=>	NIKyc4kzODR3MkKyOS=>
NB4	MnfqSpVv[3Srb36gRZN{[Xl?	NWnaOGN6PSEQvF2=	NF\tWHgzPCCq	M{foO2ROW09?	NGPiW2tE\WyuIHP5Z4xmKGG{cnXzeEBie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDhZ4N2dXWuYYTpc44h[XRicILlMWcyKHCqYYPl	MkDQNlA1QTF2NEC=
NB4	NYDxTlhHU2mwYYPlJGF{e2G7	NYe5XJQyPSEQvF2=	MYWyOEBp	MmXRSG1UVw>?	MYXJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iYXPleJlt[XSnIIT1ZpVtcW5ibHX2[Yw>	M3mwZlIxPDlzNESw
NB4	NWjxRY1uTnWwY4Tpc44hSXO\|YYm=	MoTmOUDPxE1?	M2jHV\|I1KGh?	M122b2ROW09?	M1j2T2lv\HWldHnvckBw\iCyMkHXRWYyN0OLUEGg[ZhxemW\|c3nvci=>	Ml31NlA1QTF2NEC=
NB4	MlrzT4lv[XOnIFHzd4F6	MUK1JO69VQ>?	M{my[\|I1KGh?	MlTSSG1UVw>?	M3\Zc2lvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDobZN1d26nIFizJIFk\XS7bHH0bY9v	NVTqd5ZwOjB2OUG0OFA>
NUGC3	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrHTVUxRTJwOUSg{txO	NUm5XXExOjB6NUC5O\|E>
A549	M4r5TGZ2dmO2aX;uJGF{e2G7	M{\QfVUh\|ryP	M3vNT\|MhcA>?	M{\RR2ROW09?	NXn0N4JxUW6mdXP0bY9vKG:oIHH1eI9xcGGpeTDpckBpfW2jbjDBOVQ6KGOnbHzzJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIFzDN2lK	M3n5fVIxQDV3MkC4
HUT78	NXK1dmJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGC2VlQ4OiCq	M4njVmROW09?	M3roT2dKPTB;MD6zJO69VQ>?	M{ThdlIxQDh2MkC4
U937	NE\4XnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4LrSFczKGh?	MVPEUXNQ	NXPyV4FTT0l3ME2wMlM6KM7:TR?=	NX;CS\|hYOjB6OESyNFg>
A431	NYTB[GdoS3m2b4TvfIlkKEG\|c3H5		MknEO\|IhcA>?		NX[4WJBlS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTR\|MTDj[YxteyCxdnXy[ZhxemW\|c3nu[{BGT0[UIIfpeIghUUN3MDDv[kA1NjJizszN	Mn6xNlExQDB4Mkm=
A549	M{TZSmN6fG:2b4jpZ{BCe3OjeR?=		M3faN\|czKGh?		NV;CbGprS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCxdnXy[ZhxemW\|c3nu[{BJTEGFIIfpeIghUUN3MDDv[kAyNjhizszN	NV7CblBrOjFyOEC2Nlk>
CAL27	MmHzR5l1d3SxeHnjJGF{e2G7		NHrBZ3I4OiCq		NH;JUGFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBESUx{NzDj[YxteyCxdnXy[ZhxemW\|c3nu[{BGT0[UIIfpeIghUUN3MDDv[kA{NjJizszN	NVzpd5JjOjFyOEC2Nlk>
HeLa	NUnJc3lsS3m2b4TvfIlkKEG\|c3H5		NFPNTYo4OiCq		NH3Pe2JEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\UyjIHPlcIx{KG:4ZYLlfJBz\XO\|aX7nJGhFSUNid3n0bEBKSzVyIH;mJFEvPSEQvF2=	NIjxS2UzOTB6ME[yPS=>
Sf21	NIHIc4pMcW6jc3WgRZN{[Xl?		M2TrfFMhcA>?		NXrF[WJ6UW6qaXLpeIlwdiCxZjDGcIFoKHSjZ3fl[EBpfW2jbjDy[YNwdWKrbnHueEBJTEGFODDlfJBz\XO\|ZXSge4l1cCCLQ{WwJI9nKDFwMjFOwG0>	MoPmNlExQDB4Mkm=
SKBR3	M4LPfGN6fG:2b4jpZ{BCe3OjeR?=		NYTXNXB{PzJiaB?=		M3nLdGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNMSlJ\|IHPlcIx{KG:4ZYLlfJBz\XO\|aX7nJGhGWjJid3n0bEBKSzVyIH;mJFIvPiEQvF2=	NE\welEzOTB6ME[yPS=>
SKOV3	NYm1OWdTS3m2b4TvfIlkKEG\|c3H5		MkO1O\|IhcA>?		M3zsTmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNMV1Z\|IHPlcIx{KG:4ZYLlfJBz\XO\|aX7nJGhGWjJid3n0bEBKSzVyIH;mJFIvOiEQvF2=	NHvhVZkzOTB6ME[yPS=>
COR-L23	M1PN[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\HNVAh\|ryP	NYXs[YdiPzJiaB?=	Ml;ISG1UVw>?	NFvJdm9IUTVyPUGuNUDPxE1?	NXS3cXVLOjFyOEC2OFc>
DU145	NEm2WZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rIWlExKM7:TR?=	MYq3NkBp	M1X0UWROW09?	NX3ySXVKT0l3ME2xMlA2KM7:TR?=	NG\HbWEzOTB6ME[0Oy=>
LoVo	M1HFS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfzNVAh\|ryP	NXfsdZVPPzJiaB?=	MX\EUXNQ	MVnHTVUxRTFwNzFOwG0>	NV7VN2xWOjFyOEC2OFc>
MCR5-SV2	M2PvWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWKxNEDPxE1?	NGfoTWo4OiCq	MlTmSG1UVw>?	MWjHTVUxRTJwMTFOwG0>	M3vBPFIyODhyNkS3
HCT116	M{Xqe2tqdmG\|ZTDBd5NigQ>?	M4mxV\|MxKM7:TR?=	M{T3W\|MxKGh?	MmnuSG1UVw>?	MUDJcohq[mm2aX;uJI9nKEiGQVO2JIF{e2W\|c3XkJIF{KGmwZIXjeIlwdiCxZjDhcJBp[S22dXL1cIlvKGGlZYT5cIF1cW:w	MUGyNVA5ODZ2Nx?=
HCT116	M3PDemtqdmG\|ZTDBd5NigQ>?	NF3qelI{OCEQvF2=	NVPVSlNiOzBiaB?=	NH;0Ro9FVVOR	MU\Jcohq[mm2aX;uJI9nKEiGQVOxJIF{e2W\|c3XkJIF{KGmwZIXjeIlwdiCxZjDobZN1d26nIFizT\|kh[WOndInsZZRqd25?	NWrkcZBiOjFyOEC2OFc>
U937	MXvLbY5ie2ViQYPzZZk>	NUjpT2tWPSEQvF2=	MmTQNlQhcA>?	NXfFfZlSTE2VTx?=	Mn20TY5pcWKrdHnvckBw\iCqaYP0c45mKGGlZYT5cJRz[W6\|ZnXyZZNmKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIH;mJIFk\XS7bHH0bY9vKG:oIHjpd5RwdmViSEOgZZQhUzl?	NFizTZAzOTJ7MkS5Ni=>
U937	NV;QZZprU2mwYYPlJGF{e2G7	M33hNFUh\|ryP	NXPkdFg6OjRiaB?=	NUPkfVg1TE2VTx?=	NV3teYwyUW6qaXLpeIlwdiCxZjDobZN1d26nIHHj[ZR6dHS{YX7z[oVz[XOnIHHzd4V{e2WmIHHzJIlv[3KnYYPlJI9nKGGlZYT5cIF1cW:wIH;mJIhqe3SxbnWgTFMh[XRiS{G4	NELMOlIzOTJ7MkS5Ni=>
U937	NYTIUnFoU2mwYYPlJGF{e2G7	NGfleIs2KM7:TR?=	NFiyfJgzPCCq	NHy5OWdFVVOR	M3;LR2lvcGmkaYTpc44hd2ZiaHnzeI9v\SCjY3X0fYx1emGwc3\ldoF{\SCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDv[kBx[W5vYXPleJlt[XSnZDDobZN1d26nIFi0JIxmfmWu	NX7Jd5NQOjF{OUK0PVI>
U937	MlnST4lv[XOnIFHzd4F6	NF70e\|A2KM7:TR?=	M33Wb\|E2KG2rbh?=	M1vXWGROW09?	MUTJcohq[mm2aX;uJI9nKGirc4TvcoUh[WOndInseJJidnOoZYLhd4Uh[XO\|ZYPz[YQh[XNiaX7jdoVie2Vib3[gbIl{fG:wZTDIN{Bi[2W2eXzheIlwdiCuZY\lcC=>	NIKyOWgzOTJ7MkS5Ni=>
A2780	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlvkPVYhcA>?	MlLqSG1UVw>?	M3npRWlEPTB;MT62NkDPxE1?	M3HFUlIyPjN2NEOw
COLO205	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFTTR3M6PiCq	M4D5SmROW09?	MmTrTWM2OD1{LkGyJO69VQ>?	MVyyNVY{PDR\|MB?=
Hep3B	M4PhU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYPFbmhbPDhiaB?=	MlzhSG1UVw>?	NYjORnFYT0l3ME2xMlIyKM7:TR?=	NXPKRlZSOjF5MUKxOFY>
GM11272	MULGeY5kfGmxbjDBd5NigQ>?	NYnVb4ZGOTByIH7N	M{XlWlczKGh?	MXPEUXNQ	NIf4R2tT\WGldHn2ZZRqd25ib3[gUYVEeDJibYX0ZY51KGW6cILld5Nqd25iYYSgNVAhfG9iMUCwJI5O	NYO2[4lVOjF6NEC3NVY>
CFBE41o	NE\s[29McW6jc3WgRZN{[Xl?	MlKzOUDPxE1?		MX\EUXNQ	M4rQTGRwf25icnXneYxifGmxbjDv[kBJTEGFNzDheEAxNjJidH:gOUB2VQ>?	MlzmNlE6QDR7NUi=
CFBE41o	MnLsSpVv[3Srb36gRZN{[Xl?	NUK3cXJvOSEQvF2=	M{TBU\|I1KGh?	MYfEUXNQ	MUTS[ZN1d3KjdHnvckBw\iCFRmTSJIRmdHSjRkWwPEBufXSjboSgeJJi\m[rY3vpcochfG9iY3XscEB{fXKoYXPlJIF{KGeueXPv[o9zdXN?	NH7WV\|kzOTl6NEm1PC=>
DU145	M3P3dGtqdmG\|ZTDBd5NigQ>?	M2f4NlIvPSEQvF2=	M2DPTVI1KGh?	M1nZVmROW09?	MXLJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhfXC{ZXf1cIF1cW:wIH;mJJAzOXejZkGgdJJwfGWrbjDlfJBz\XO\|aX;u	MUSyNlI3ODF4Nh?=
DU145	MkLOT4lv[XOnIFHzd4F6	MoHFOUDPxE1?	M3fFSFI1KGh?	M3n6dGROW09?	M2HoOWlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCqaYP0c45mKEh2IHHj[ZR6dGG2aX;u	M2fPWVIzOjZyMU[2
DU145	Moq3T4lv[XOnIFHzd4F6	MlPxOUDPxE1?	M1npPVI1KGh?	MoqwSG1UVw>?	M3LOUGlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCqaYP0c45mKEh\|IHj5dIVz[WOndInsZZRqd25?	NHjiNIQzOjJ4MEG2Oi=>
786-0	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH;6c403NjJizszN	NILqXZM4OiCq	MVzEUXNQ	MkDjS2k2OD1\|LkKg{txO	M3i0S\|IzPDN3Nk[5
A498	NEHDOFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGS2RpI3NjJizszN	NG\iVHY4OiCq	MkDlSG1UVw>?	MVHHTVUxRTFwNjFOwG0>	M2TGflIzPDN3Nk[5
A549/ATCC	NX\1TZVUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDldZk3NjJizszN	MYS3NkBp	M2DETmROW09?	NHOzVGdIUTVyPUGuOkDPxE1?	NWfacotrOjJ2M{W2Olk>
ACHN	MmX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWH2d\|hzPi5{IN88US=>	M3P2VVczKGh?	M4f4VWROW09?	NHz1e\|JIUTVyPUGuN{DPxE1?	MX6yNlQ{PTZ4OR?=
BT549	NILVOm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHjWS3o3NjJizszN	Mn3iO\|IhcA>?	Ml;uSG1UVw>?	MUTHTVUxRTFwMzFOwG0>	NWOwRlBDOjJ2M{W2Olk>
EKVX	NUe5ZYdQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXr4XW9rPi5{IN88US=>	M4DIcVczKGh?	MnfQSG1UVw>?	M1eyemdKPTB;MT6zJO69VQ>?	NFPmZWczOjR\|NU[2PS=>
HCT15	M3;WZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjjNFRnPi5{IN88US=>	M3vWSFczKGh?	MVTEUXNQ	M3vyVmdKPTB;Mj61JO69VQ>?	NVXMeG9nOjJ2M{W2Olk>
HOP92	NEj1elJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYi2MlIh\|ryP	Mom5O\|IhcA>?	MnvYSG1UVw>?	NH7nO4lIUTVyPUSg{txO	MUSyNlQ{PTZ4OR?=
IGROV1	M2DPO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjpRlR6Pi5{IN88US=>	NXTaN3JlPzJiaB?=	MoqzSG1UVw>?	M1:wcmdKPTB;MT6zJO69VQ>?	MX:yNlQ{PTZ4OR?=
LOXIMVI	NGLyPFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUi2MlIh\|ryP	NFXvSXk4OiCq	NVXmXY9FTE2VTx?=	NGrndJNIUTVyPUGg{txO	M1noXVIzPDN3Nk[5
M14	NInZXGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIrPVoM3NjJizszN	NF3FfJg4OiCq	NXGzXIpsTE2VTx?=	NEXaNXRIUTVyPUGuN{DPxE1?	MkPxNlI1OzV4Nkm=
MALME-3M	NILBXZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{jQclYvOiEQvF2=	NEDXWHQ4OiCq	MkDoSG1UVw>?	MnvjS2k2OD1yLkOyJO69VQ>?	NGO3THczOjR\|NU[2PS=>
MCF10A	M4m0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPNOk4zKM7:TR?=	M2\pSVQ5KGh?	M3TRPWROW09?	MlLuS2k2OD17Lk[g{txO	NELiSoYzOjR\|NU[2PS=>
MDA-MB-435	M2HFb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NETlS2U3NjJizszN	NYfzNHlpPzJiaB?=	MYfEUXNQ	MnOzS2k2OD1yLkWg{txO	NI\jfYszOjR\|NU[2PS=>
MDA-MB-468	M4HQPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7UXW43NjJizszN	NVTUZ3JQPzJiaB?=	MULEUXNQ	M{TC[GdKPTB;MD62N{DPxE1?	Mn64NlI1OzV4Nkm=
MOLT4	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUG2MlIh\|ryP	M2D3V\|czKGh?	MmjySG1UVw>?	MoTpS2k2OD1yLkSg{txO	MUWyNlQ{PTZ4OR?=
NCI-ADR-RES	NFLKSI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3nYO\|YvOiEQvF2=	MkPtO\|IhcA>?	NH7qNXNFVVOR	Mli2S2k2OD1yLkG2JO69VQ>?	M2\HfFIzPDN3Nk[5
NCI-H23	NFLqcGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3\0XlYvOiEQvF2=	M3jWRVczKGh?	MWTEUXNQ	MnTIS2k2OD1zIN88US=>	NVnMNYRiOjJ2M{W2Olk>
NCI-H322M	M1\YN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULyOWtQPi5{IN88US=>	NIiyN\|U4OiCq	MmG4SG1UVw>?	NIXXO4VIUTVyPUCuO\|kh\|ryP	Mlr4NlI1OzV4Nkm=
NCI-H460	M1yyTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLXOk4zKM7:TR?=	NIfLdGI4OiCq	M{LsWWROW09?	NVHZOoM1T0l3ME2wMlc6KM7:TR?=	M1u3PFIzPDN3Nk[5
NCI-H522	NWj6VGh[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEfu[og3NjJizszN	NF\NNJQ4OiCq	NUTNbpRWTE2VTx?=	NVfvOnFyT0l3ME2wMlUh\|ryP	MmHiNlI1OzV4Nkm=
OVCAR3	NEXIS3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn\pOk4zKM7:TR?=	NGXCN284OiCq	NGf2SYNFVVOR	Mkj6S2k2OD1zLkOg{txO	MWKyNlQ{PTZ4OR?=
OVCAR4	NG\we\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmTwOk4zKM7:TR?=	MYe3NkBp	M{m3TmROW09?	NFrrdGRIUTVyPUSg{txO	MoH3NlI1OzV4Nkm=
OVCAR5	M4TENWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2nRd\|YvOiEQvF2=	NVLXWXpxPzJiaB?=	M2rETGROW09?	NU\MXZRVT0l3ME2wMlc6KM7:TR?=	NVPnNXU2OjJ2M{W2Olk>
OVCAR8	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX7tRmdZPi5{IN88US=>	MXW3NkBp	M{TzNWROW09?	M3XKSmdKPTB;MD61JO69VQ>?	MUSyNlQ{PTZ4OR?=
RXF393	M{fuR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYP2bGtSPi5{IN88US=>	M3mzS\|czKGh?	NV20WVJkTE2VTx?=	NEnEU3pIUTVyPUGuN{DPxE1?	NWjEdFdCOjJ2M{W2Olk>
SF268	MlzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mkm1Ok4zKM7:TR?=	NX;ZflVYPzJiaB?=	M3fzcWROW09?	Mmn5S2k2OD1zLk[g{txO	MVOyNlQ{PTZ4OR?=
SF295	M2DJOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHHaXYg3NjJizszN	MVi3NkBp	NYDRXnRKTE2VTx?=	MVLHTVUxRTFwNjFOwG0>	M4S5b\|IzPDN3Nk[5
SF539	NFf4ZnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTObpdGPi5{IN88US=>	NYHQUHpVPzJiaB?=	MU\EUXNQ	M{TRSGdKPTB;MjFOwG0>	MYeyNlQ{PTZ4OR?=
SK-MEL-2	NGS3U4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYe2MlIh\|ryP	M3nybFczKGh?	NIXXPWlFVVOR	M1u1SmdKPTB;MT6zJO69VQ>?	MofsNlI1OzV4Nkm=
SK-MEL-28	M3y4WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFXp[XM3NjJizszN	M3LLPVczKGh?	MVTEUXNQ	MnHRS2k2OD1zIN88US=>	MXWyNlQ{PTZ4OR?=
SK-MEL-5	Mnu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4LLUFYvOiEQvF2=	NFvpbWs4OiCq	MlP6SG1UVw>?	MUnHTVUxRTBwNkOg{txO	MoLCNlI1OzV4Nkm=
SKOV3	NFfKWYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWG5cnRPPi5{IN88US=>	NFLpcYs4OiCq	MWfEUXNQ	NUDESHdqT0l3ME2xJO69VQ>?	MmLvNlI1OzV4Nkm=
SN12C	M{DtUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;Qb5pkPi5{IN88US=>	NFvpNoQ4OiCq	M3vOTWROW09?	NI\Z[opIUTVyPUKg{txO	NYfGV3NoOjJ2M{W2Olk>
SNB19	M2fMeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUi2MlIh\|ryP	MYe3NkBp	MUjEUXNQ	MnrCS2k2OD1yLk[zJO69VQ>?	M2\sWlIzPDN3Nk[5
SNB75	NGfSc\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXy2MlIh\|ryP	MWW3NkBp	NIPoeIdFVVOR	M2juO2dKPTB;MD63PUDPxE1?	MnPuNlI1OzV4Nkm=
SR	M4DCWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{TCWlYvOiEQvF2=	NIPxUYY4OiCq	MUDEUXNQ	NHfoSnRIUTVyPUCuOEDPxE1?	NYXKOXBKOjJ2M{W2Olk>
T47D	NWLDWWhyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3iWGl1Pi5{IN88US=>	M1fQSlczKGh?	M37jUmROW09?	NF6ybIdIUTVyPUCuOUDPxE1?	NVfHcYJmOjJ2M{W2Olk>
TK10	NEPFNldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmG4Ok4zKM7:TR?=	NFnVeno4OiCq	NVPDfYxmTE2VTx?=	MUXHTVUxRTBwNkOg{txO	MV2yNlQ{PTZ4OR?=
UACC257	MkPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXO2MlIh\|ryP	M2Dpc\|czKGh?	NILTeYhFVVOR	MkDtS2k2OD1yLkWg{txO	M13SfFIzPDN3Nk[5
UACC62	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlnqOk4zKM7:TR?=	NYf3NZJ1PzJiaB?=	NWXkRWgyTE2VTx?=	M4noeWdKPTB;MD60JO69VQ>?	MYGyNlQ{PTZ4OR?=
UO31	NYHzZ2VvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUm2MlIh\|ryP	MnL2O\|IhcA>?	MknoSG1UVw>?	M{LFT2dKPTB;MD61JO69VQ>?	MVqyNlQ{PTZ4OR?=
Hep3B	MoKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWq0PEBp	NHH3Z4NFVVOR	MlvxS2k2OD1yLk[5JO69VQ>?	NXn3T4F1OjJ2M{m4OlM>
BE(2)-C	MmfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MkHvO\|IhcA>?	Mnn3SG1UVw>?	MmHBTWM4OD1{IN88US=>	NF;uO2UzOjl\|MkOxOi=>
Bel7402	Mk\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1Ppe\|czKGh?	NH3RXmtFVVOR	MWfHTVkxRTF5IN88US=>	NWnwR4ZyOjNyNkGzO\|Y>
Bel7404	NFGyUm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{T1PFczKGh?	MWPEUXNQ	Ml\YS2k6OD1zODFOwG0>	MoToNlMxPjF\|N{[=
BGC823	NIjnUIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3X1clczKGh?	NHThellFVVOR	NF7lemlIUTlyPUeuOUDPxE1?	MmXrNlMxPjF\|N{[=
MGC803	NV3RVXl{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXXDNGR1PzJiaB?=	NV76cnI3TE2VTx?=	NXiwVG1UT0l7ME2xNE45KM7:TR?=	NVXDTW96OjNyNkGzO\|Y>
SGC7901	NUi5[HJoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYfndJlyPzJiaB?=	NYLLUWI2TE2VTx?=	NF\Q[YNIUTlyPUmuOEDPxE1?	MV2yN\|A3OTN5Nh?=
SKHEP1	NWTPW\|h[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnXaO\|IhcA>?	NEHCZmhFVVOR	NYTxW5pST0l7ME2xO{DPxE1?	NULyemRZOjNyNkGzO\|Y>
SMMC7721	NUPHPZJTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MV:3NkBp	M3PUdmROW09?	MWnHTVkxRTJyIN88US=>	MUWyN\|A3OTN5Nh?=
NUGC3	MnnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV:xNEDPxE1?			NUXRWlFqT0l;Mj65OEDPxE1?	MWSyN\|E3OzN\|Mh?=
A2780 CisR	NHvDWmJMcW6jc3WgRZN{[Xl?		M{O0XlE5KGh?		NXvTSmhSUW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlQ1KM7:TR?=	M{LMXVI{OjV{NkCz
CAL27 sens	MnznT4lv[XOnIFHzd4F6		M2H4fVE5KGh?		NX7iTZVkUW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlM3KM7:TR?=	M2H6TlI{OjV{NkCz
CAL27 CisR	MWLLbY5ie2ViQYPzZZk>		M4nCUlE5KGh?		MoLSTY5pcWKrdHnvckBw\iCKRFHDJJdqfGhiSVO1NEBw\iByLk[xJO69VQ>?	NYjle\|VOOjN{NUK2NFM>
KYSE-510 CisR	MonvT4lv[XOnIFHzd4F6		MVmxPEBp		MUDJcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwNUmg{txO	NVLR[lFGOjN{NUK2NFM>
KYSE-510 sens	NWryb29YU2mwYYPlJGF{e2G7		MnrjNVghcA>?		NVLPNZpJUW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlch\|ryP	M1\aXVI{OjV{NkCz
MDA-MB-231 sens	M3q3O2tqdmG\|ZTDBd5NigQ>?		MmLmNVghcA>?		MVHJcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwNkGg{txO	NWfFU2RKOjN{NUK2NFM>
MDA-MB-231 CisR	M{DIdGtqdmG\|ZTDBd5NigQ>?		NX3lcWk5OThiaB?=		M4jrZWlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD62NUDPxE1?	NH\3VYMzOzJ3Mk[wNy=>
ES2	NGjoeolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHvLbmo1QCCq	NVz1dVJKTE2VTx?=	MYXJR\|UxRTF{Lkeg{txO	NInPfpIzOzR7M{S0PS=>
MDA-MB-231	NYOzOYoxU2mwYYPlJGF{e2G7	M{LXNlExKM7:TR?=	MkHTN\|AhdWmw	MYPEUXNQ	NIrabW1KdmirYnn0bY9vKG:oIFjERWMz[Q>?	M4HJXVI{PDl\|NES5
MDA-MB-231	NVrkboRvU2mwYYPlJGF{e2G7	MkfhNUDPxE1?	Ml3xNlQhcA>?	NXLFZ3VWTE2VTx?=	MWjJcohq[mm2aX;uJI9nKEiGQVO2JIF{e2W\|c3XkJIF{KGGlZYT5cIF1cW:wIHzleoVteyCxZjD0eYJ2dGmw	NILM[FUzOzR7M{S0PS=>
HS68	Mnm5R5l1d3SxeHnjJGF{e2G7	MoP5NVAh\|ryP	MVi3NkBp	MnLTSG1UVw>?	M{XlcGlEPTB;ND62JO69VQ>?	MWGyN\|U4ODV2Mh?=
MEF	NFf6NVlEgXSxdH;4bYMhSXO\|YYm=	MVyxNEDPxE1?	NIm1UFM4OiCq	MkW3SG1UVw>?	Mk\oTWM2OD12LkSg{txO	MnPDNlM2PzB3NEK=
BGC823	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NH\lSm1FVVOR	MWHHTVUxRTNwMEmg{txO	NVvmXIVjOjN4MEG3NFY>
High5	NWfJOGx7U2mwYYPlJGF{e2G7		NVHkVVYzOjRiaB?=		MnLPTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCKRFHDOkB4cXSqIFnDOVAhd2ZiMD6wPUDPxE1?	MWSyN\|YxOjV{Mx?=
High5	NEDK[FhMcW6jc3WgRZN{[Xl?		MlvVNlQhcA>?		NVi0XHNRUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDISGFEOSC5aYToJGlEPTBib3[gNE4yOiEQvF2=	NVjuZWJtOjN4MEK1NlM>
High5	M1fyd2tqdmG\|ZTDBd5NigQ>?		MWqyOEBp		M4i3VmlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiSFTBR\|Mhf2m2aDDJR\|UxKG:oIECuNVch\|ryP	M2\xdVI{PjB{NUKz
A549	M162NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXPEUXNQ	NYHiZmlZUUN3ME2xMlA4QSEQvF2=	NGS3R\|QzOzZ2NEKxNC=>
HCT116	NEfLepBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M3zT[2ROW09?	MmTMTWM2OD1yLke1O{DPxE1?	MlT0NlM3PDR{MUC=
K562	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NYKzbm16TE2VTx?=	MVjJR\|UxRTBwNkS1JO69VQ>?	Mn;kNlM3PDR{MUC=
GBC-SD	MknkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW[1JO69VQ>?	MmDrO\|IhcA>?	Mlr6SG1UVw>?	NGq5d3ZKSzVyPUG0Mlgh\|ryP	MnfpNlM4ODd{NkC=
HGC27	NGn0RodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYq1JO69VQ>?	M4H2NVczKGh?	NFPMW5pFVVOR	NHHsR5hKSzVyPUWuOEDPxE1?	NUfxbZJrOjN5MEeyOlA>
HL60	MWHLbY5ie2ViQYPzZZk>	Mn[3OUDPxE1?	NEH2SnYzPCCq	Mn7KSG1UVw>?	NUPMRmVwUW6qaXLpeIlwdiCxZjDISGFE	MViyN\|cxPzJ4MB?=
Vero	M4rMVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4XpdFczKGh?	MXLEUXNQ	NVPFS\|dCUUN3ME2wMlkh\|ryP	MnXVNlM4QDZ2NUK=
NCI60	MoWyR5l1d3SxeHnjJGF{e2G7		MYK0PEBp	NHzqNXhFVVOR	NXHOdJNCT0l;MD61N{DPxE1?	MoTVNlQxOTV\|Mke=
SW620	MVvDfZRwfG:6aXOgRZN{[Xl?		M2D0U\|Q5KGh?	NHnacoRFVVOR	M4DQcWdKRTBwNUSg{txO	MmP6NlQxOTV\|Mke=
U251	MmrWR5l1d3SxeHnjJGF{e2G7		M3nCVVQ5KGh?	MVjEUXNQ	NFXuVGFIUT1zLkWzJO69VQ>?	MUWyOFAyPTN{Nx?=
KM12	M1P1XGN6fG:2b4jpZ{BCe3OjeR?=		M3PwZlQ5KGh?	NGLYRnlFVVOR	MoDES2k:OS56ODFOwG0>	MoewNlQxOTV\|Mke=
Hs578T	MnKyR5l1d3SxeHnjJGF{e2G7		NXTLTZA2PDhiaB?=	MWjEUXNQ	NETqfINIUT12LkizJO69VQ>?	NILlSFAzPDBzNUOyOy=>
MDA-MB-231	NFvUeINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3P5dVQ5KGh?		Mk\OTWM2OD1yLkG2JO69VQ>?	NUn5TFhPOjRyOUWwNVY>
MCF7	NGHPXYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVu0PEBp		NXHuS\|R[T0l;MD60OUDPxE1?	NUjsR\|lvOjRzMUm1OVU>
MDA-MB-435	Mn\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NULCc4VDPDhiaB?=		NH[2UnFIUT1yLki4JO69VQ>?	MUSyOFEyQTV3NR?=
AsPC1	NEO4d3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\1N\|Ah\|ryP	MUi0PEBp	M{LFbWROW09?	NF\BWFRKSzVyPUOuOlYh\|ryP	NE\ucJkzPDF6NUO3PC=>
Jurkat E6.1	NGrhN\|hMcW6jc3WgRZN{[Xl?		M2nPSVIhcA>?	Mn72SG1UVw>?	MYrJcohq[mm2aX;uJI9nKEiGQVO0JJdqfGhiSVO1NEBw\iByLkC0JO69VQ>?	NGfwb5MzPDJ4MUi2Ni=>
KG1	NX\jV2MyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFXCcGI1QCCq		NIG1W4VKSzVyPUGuNVUh\|ryP	NG[yZZIzPDV{NUCwNy=>
HEL	NULYc2hQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{TzbVQ5KGh?	NHTvNndFVVOR	MWDJR\|UxRTBwNEmg{txO	NWPkb4J{OjR4OUSwOVU>
HSC3	MUPDfZRwfG:6aXOgRZN{[Xl?		NFv2cIUyOiCq	MoXNSG1UVw>?	Ml63TWM2OD1yLkexJO69VQ>?	MUeyOFc3PjV4MB?=
HT-29	NIjRUohEgXSxdH;4bYMhSXO\|YYm=		NGn6fHUyOiCq	M1O5OmROW09?	MknlTWM2OD1yLkeyJO69VQ>?	NXLscIZrOjR5Nk[1OlA>
KB	MmD2R5l1d3SxeHnjJGF{e2G7		MX[xNkBp	MnPjSG1UVw>?	M2Htd2lEPTB;MD63OUDPxE1?	MmrFNlQ4PjZ3NkC=
H460	NIj4O2FEgXSxdH;4bYMhSXO\|YYm=		NX7QT2xCOTJiaB?=	MXjEUXNQ	MlfDTWM2OD1yLkiyJO69VQ>?	NGKxRWYzPDd4NkW2NC=>
MONE1	NWTXS282S3m2b4TvfIlkKEG\|c3H5		NYXkXnhGOTJiaB?=	NIHSR45FVVOR	M17uVmlEPTB;MT6xPEDPxE1?	NFPSPHUzPDd4NkW2NC=>
MKN45	NFyxfYVEgXSxdH;4bYMhSXO\|YYm=		M3zuN\|EzKGh?	M4[zSGROW09?	NYDlO4xIUUN3ME2xMlI2KM7:TR?=	NGf4OFczPDd4NkW2NC=>
TSGH	NXfjSopXS3m2b4TvfIlkKEG\|c3H5		MmSxNVIhcA>?	NGHHfIVFVVOR	MYPJR\|UxRTJwMEmg{txO	MU[yOFc3PjV4MB?=
HL60	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4HrOVczKGh?	NYXxdWFNTE2VTx?=	NHHrOIxIUTVyPUCuPVMh\|ryP	M1L6[VI1QTByNUCw
HEK293	M2HhOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWm3NkBp	NFPYfHNFVVOR	NEXKTIZIUTVyPUGzJO69VQ>?	MlzxNlQ6ODB3MEC=
Jurkat	MnfPR5l1d3SxeHnjJGF{e2G7	NEG3[IsyODBizszN	NIHIZ\|Y4OiCq		M2fKbWdKPTB;MD65JO69VQ>?	MVmyOFkxODd2Mx?=
GM15850	NH;vSZVMcW6jc3WgRZN{[Xl?	NYjOfoZoOi53IN88US=>	MnXDPVYhcA>?	M{j6XmROW09?	NUnjSno{\G:nczDuc5QhcW6qaXLpeEBJTEGFIHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGirc4TvcoUhUDNibInzbY5mKDF2IHHj[ZR6dGG2aX;uJI9nKE[[TjDn[Y5m	MoLMNVY6OjF\|Nke=
GM15850	MV3LbY5ie2ViQYPzZZk>	M{\BblIvPSEQvF2=	NFnkZlk6PiCq	NG\LdJZFVVOR	M1\jT4Rw\XNibn;0JIlvcGmkaYSgTGRCSyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBpcXO2b37lJGg1KGy7c3nu[UA2KGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	NXzOUYtWOTZ7MkGzOlc>
GM15850	NWrmeVl{U2mwYYPlJGF{e2G7	NVjhdHlKOi53IN88US=>	MVO5OkBp	MYLEUXNQ	MoW3[I9meyCwb4SgbY5pcWKrdDDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm\|aX7lJFEzKGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	NEfVZY4yPjl{MUO2Oy=>
GM15850	M4HJVWtqdmG\|ZTDBd5NigQ>?	NH;TW4czNjVizszN	M{HlXlk3KGh?	MkPKSG1UVw>?	NIfPe4Zld2W\|IH7veEBqdmirYnn0JGhFSUNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hcGm\|dH;u[UBJOyCueYPpcoUhQSCjY3X0fYxifGmxbjDv[kBHYE5iZ3Xu[S=>	MmjKNVY6OjF\|Nke=
GM15850	NE\4TmxMcW6jc3WgRZN{[Xl?	MlTwNk42KM7:TR?=	MXi5OkBp	MlSwSG1UVw>?	M2rKc4Rw\XNibn;0JIlvcGmkaYSgTGRCSyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBpcXO2b37lJGg1KGy7c3nu[UA5KGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	NGrJeYIyPjl{MUO2Oy=>
GM15850	M3TVO2tqdmG\|ZTDBd5NigQ>?	MnP5Nk42KM7:TR?=	MnzGPVYhcA>?	NFTqVpNFVVOR	NV35[ldb\G:nczDuc5QhcW6qaXLpeEBJTEGFIHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGirc4TvcoUhUDRibInzbY5mKDF4IHHj[ZR6dGG2aX;uJI9nKE[[TjDn[Y5m	M3T2WlE3QTJzM{[3
GM15850	NXzBXmJNTnWwY4Tpc44hSXO\|YYm=	MYS1JO69VQ>?	NX:xWXJzOTJiaB?=	MXTEUXNQ	NY\nNY95cGG\|IH7vJIVn\mWldDDvckBHYE5ibWLORUBmgHC{ZYPzbY9v	M1PHOFE3QTJzM{[3
U937	MnLuT4lv[XOnIFHzd4F6	NX\USZFCPSEQvF2=	NVrpO\|hSOjRiaB?=	NGXLVGtFVVOR	MoHkbIF{KG6xIHXm[oVkfCCxbjDhcJBp[SC2dXL1cIlvKGGlZYT5cIF1cW:w	NGe5eXIyPzR2N{e1NC=>
U937	M4DJemtqdmG\|ZTDBd5NigQ>?	MonpNUDPxE1?	M{DyVlI1KGh?	MoGzSG1UVw>?	MljVbIF{KG6xIHXm[oVkfCCxbjDhcJBp[SC2dXL1cIlvKGGlZYT5cIF1cW:w	NHXBSYYyPzR2N{e1NC=>
PANC1	MVLGeY5kfGmxbjDBd5NigQ>?	NULoVGZHOSEQvF2=	MnjtNlQhcA>?		M3LDd4Rw\XNibn;0JIlv[3KnYYPlJIlvKHB{N3vpdFEh\2WwZTDlfJBz\XO\|aX;u	M1XBZVE4PTh6N{S0
PANC1	MlzrSpVv[3Srb36gRZN{[Xl?	NHHqenEyKM7:TR?=	NVT1[I9MPDhiIHi=		NXPNcZhI\G:nczDuc5QhcW6lcnXhd4UhcW5icEK3b4lxOSCpZX7lJIV5eHKnc4Ppc44>	NXH4bFh7OTd3OEi3OFQ>
Caco-2	MX3GeY5kfGmxbjDBd5NigQ>?	MV61JO69VQ>?	MVOyOEBp	NILlNXJFVVOR	M4niVoRw\XNibn;0JIlv\HWlZTDQNlFYSUZzIHflcoUh\XiycnXzd4lwdg>?	MmXvNlAyPDN6NEC=
SCC4	NYTGVYlyTnWwY4Tpc44hSXO\|YYm=	NIPsXW8yKM7:TR?=	Mn;CNVAhdWmw	Mmn2SG1UVw>?	M1SxW4hieyCwbzDh[49vcXO2IHHjeIl3cXS7IHH0JHZFWiCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhS1mSMkSg[4Vv\SCneIDy[ZN{cW:w	MknpNlA1PTJ{MkW=
A549	MYHGeY5kfGmxbjDBd5NigQ>?	NV[zZW1pPSEQvF2=	NHnLW5g{KGh?	M3jYVWROW09?	M1vTc4Rw\XNibn;0JIlv\HWlZTDheZRweGijZ4mgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iTFOzTWk>	NGrM[3QzODh3NUKwPC=>
HCT116	NUW5TI9CU2mwYYPlJGF{e2G7	NVnUV4tFOC5\|IN88US=>	NHfGbXI{OCCq	MULEUXNQ	M1LqR4Rw\XNibn;0JIlvcGmkaYSgTGRCSzFiYYPz[ZN{\WRiYYOgbY5lfWO2aX;uJI9nKGirc4TvcoUhUDONOTDhZ4V1gWyjdHnvci=>	MX[yNVA5ODZ2Nx?=
HepG2	NE\lXWZHfW6ldHnvckBCe3OjeR?=	NGP1R3QyOCEQvF2=	MXGyOEBp	M3nQZmROW09?	MULkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m\|IHHzd4V{e2WmIHHzJIh6eGW{YXPleJlt[XSrb36gc4YheDV\|	M1fsSVIyPTR6NUiy
GM11272	NE\oSJhHfW6ldHnvckBCe3OjeR?=	NHntWpIxNjFizszN	MknhO\|IhcA>?	NHPGUnZFVVOR	M3PiSoRw\XNibn;0JJJm[WO2aY\heIUhVWWFcEKgcZV1[W62IHX4dJJme3Orb36=	M3HOe\|IyQDRyN{G2
MDA-MB-231	MXnLbY5ie2ViQYPzZZk>	MUGxNEDPxE1?	M2\lO\|UhdWmw	NGfGXmhFVVOR	NGfHeIVld2W\|IH7veEBqdmirYnn0JGhFSUN{YR?=	M{HpO\|I{PDl\|NES5
MDA-MB-231	Mn3NT4lv[XOnIFHzd4F6	MmfqNUDPxE1?	MkS2NlQhcA>?	MmnYSG1UVw>?	Moj1[I9meyCwb4SgbY5pcWKrdDDISGFEPiCjc4Pld5Nm\CCjczDhZ4V1gWyjdHnvckBt\X[nbIOgc4YhfHWkdXzpci=>	MkjkNlM1QTN2NEm=
K562	MoPVT4lv[XOnIFHzd4F6				NE\PclJld2W\|IH7veEBqdmirYnn0JGhFSUN?	NWnWe5l3OjN3OUGxNVE>
Jurkat	NYjNSFQ3S3m2b4TvfIlkKEG\|c3H5	MYKyNEDPxE1?	NFHtelM4OiCq	MV7EUXNQ	NGLXfHBvdyCleYTveI95cWOrdImgZZN{\XO\|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44>	MnnQNlQ{ODR\|NEi=
HCT116	M1TvcGFxd3C2b4Ppd{BCe3OjeR?=	MWmzJO69VQ>?	NYLseZFtOjRiaB?=	MXnEUXNQ	M3W4SYRw\XNibn;0JIlv\HWlZTDhdI9xfG:\|aYOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5icEWzJJBzd3SnaX6gcIV3\Wx?	NFT3bIMzPDd4NkW2NC=>
KASUMI-1	M{\vd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1u1T2lEPTB;OUmuNVchdk1?	MUfTRW5ITVJ?
KARPAS-45	M2foeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTF5Mz64PUBvVQ>?	MVHTRW5ITVJ?
BHT-101	NF\iZo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYP3WJdbUUN3ME2yOFQvOThibl2=	M4Hj[XNCVkeHUh?=
H9	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1jJR2lEPTB;MkW1MlA1KG6P	MYXTRW5ITVJ?
PA-1	Mm\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3e3UmlEPTB;Mki2MlI3KG6P	Mlu1V2FPT0WU
NEC8	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVzJR\|UxRTJ6OT6zPEBvVQ>?	MkmxV2FPT0WU
MHH-PREB-1	NILEPWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX7aOlVsUUN3ME2yPVQvPTNibl2=	Mo[1V2FPT0WU
NB7	NGPUcFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTwTWM2OD1\|NEWuO\|Qhdk1?	NFTsb3lUSU6JRWK=
A3-KAW	NWPUdVhST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2LSUWlEPTB;NECwMlU6KG6P	NX7XSYZJW0GQR1XS
NB69	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVnJR\|UxRTRzMT63NUBvVQ>?	NUTBWIpUW0GQR1XS
EoL-1-cell	MnLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWrP[3E5UUN3ME20OVQzPSCwTR?=	MoTkV2FPT0WU
CHP-212	NIqweHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M17neGlEPTB;NEW3MlU{KG6P	NVzrfYZDW0GQR1XS
C2BBe1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTR5Mj6xPUBvVQ>?	MYLTRW5ITVJ?
697	MnfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NICyZ5lKSzVyPUS3N{41OSCwTR?=	NG[2[FdUSU6JRWK=
BCPAP	NXnENoFHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHzrT5VKSzVyPUWwNU41OiCwTR?=	MkjRV2FPT0WU
L-363	M2Czfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoX5TWM2OD13MEOuNUBvVQ>?	M32zenNCVkeHUh?=
ES8	NIH0OXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXfXZ4pEUUN3ME21NlMvPTNibl2=	NH3xPXNUSU6JRWK=
BE-13	NVjmZZFuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUHWdmp3UUN3ME21NlYvQTZibl2=	NHG2bGVUSU6JRWK=
CTB-1	Mn;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV3vSFRPUUN3ME21N\|cvQTJibl2=	NH\UNHlUSU6JRWK=
HD-MY-Z	NH65UJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MofVTWM2OD13M{iuNVMhdk1?	MnS0V2FPT0WU
NKM-1	M2myeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2qw[mlEPTB;NUS0MlI4KG6P	M3jiSXNCVkeHUh?=
NCI-H720	M1nMSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX;GOG5iUUN3ME21OlAvOThibl2=	M1GxUXNCVkeHUh?=
KY821	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;RTWM2OD13NkOuNlUhdk1?	NV7tSWJ3W0GQR1XS
OVCAR-5	NWLISWFST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTV5Nj6xNUBvVQ>?	NFXa[XNUSU6JRWK=
CTV-1	MkjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlnoTWM2OD13OEGuOVYhdk1?	NXnFPG1XW0GQR1XS
P12-ICHIKAWA	MoqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWDRRXhWUUN3ME21PVYvPTFibl2=	MXrTRW5ITVJ?
DB	MoW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIPIS3NKSzVyPUW5PE42PyCwTR?=	MYPTRW5ITVJ?
CHL-1	NFr4eZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYDYWZFEUUN3ME22OFIvODhibl2=	MX\TRW5ITVJ?
A4-Fuk	M1j6[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH;LWmJKSzVyPU[0OE46OSCwTR?=	M3TEXHNCVkeHUh?=
MV-4-11	NVTLOI16T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkXpTWM2OD14NUmuNUBvVQ>?	NVq2TpZQW0GQR1XS
RPMI-8226	MlLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NETDZYVKSzVyPU[3PE4yQCCwTR?=	M1fZd3NCVkeHUh?=
NB14	MmnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFnQdXhKSzVyPU[5Ok46PSCwTR?=	MlXwV2FPT0WU
DOHH-2	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3XKbmlEPTB;N{C2MlY5KG6P	M{[ybXNCVkeHUh?=
D-423MG	M2fQbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH60UlNKSzVyPUewOk45QSCwTR?=	NEWwbYNUSU6JRWK=
D-283MED	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NG\xSGFKSzVyPUexOE4yPCCwTR?=	M3jHOHNCVkeHUh?=
ES1	NGPQS25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVvMZ4hsUUN3ME23NlQvPCCwTR?=	NXjtfnZbW0GQR1XS
GOTO	NV7IeW1kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVnmeINEUUN3ME23NlkvOTJibl2=	MmDPV2FPT0WU
NCI-H209	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXy0Noh7UUN3ME23NlkvQSCwTR?=	MY\TRW5ITVJ?
MOLT-13	MlLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2XCSWlEPTB;N{O4Mlk5KG6P	MkG0V2FPT0WU
ATN-1	Mmr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV3YdFhyUUN3ME23OFAvOjhibl2=	MkLCV2FPT0WU
DU-4475	M4nwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MknMTWM2OD15NUGuPVEhdk1?	NGPyS5BUSU6JRWK=
NB10	NYjibZprT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHfRSGpKSzVyPUe1NU46OiCwTR?=	MmfRV2FPT0WU
KG-1	NIPnTFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkTVTWM2OD15N{WuOFUhdk1?	MlruV2FPT0WU
MOLT-4	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVXJR\|UxRTd6Nz60OkBvVQ>?	NG\5RnZUSU6JRWK=
TE-1	NVPsRnpxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWHJR\|UxRTd7MT6xJI5O	NYC4dm03W0GQR1XS
SBC-1	M37pNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{LiPGlEPTB;N{mzMlg1KG6P	NHHSWIFUSU6JRWK=
HEL	NGnZ[ohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHj1OpRKSzVyPUiwOk4xQCCwTR?=	MWfTRW5ITVJ?
SK-MEL-2	NELROFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWrjSWw{UUN3ME24NFkvPDRibl2=	MkK0V2FPT0WU
KU812	NWr6OZgyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M13WcGlEPTB;OEGzMlEhdk1?	M4DPd3NCVkeHUh?=
RPMI-8866	M3[4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXTHfVA6UUN3ME24NVMvPjdibl2=	NYX0XGtoW0GQR1XS
ALL-PO	Mlj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV\JR\|UxRThzND62OkBvVQ>?	MlHHV2FPT0WU
LU-139	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{[zZ2lEPTB;OEKyMlg3KG6P	M330cXNCVkeHUh?=
RS4-11	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4fLTGlEPTB;OEOyMlQ2KG6P	NGrYUJNUSU6JRWK=
EW-18	NXnyVWh3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3v3SmlEPTB;OEOyMlk3KG6P	NYPIfGpRW0GQR1XS
P30-OHK	M3PoPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGf1OWxKSzVyPUizOU44KG6P	MoLpV2FPT0WU
D-566MG	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoLhTWM2OD16M{iuOlIhdk1?	MofVV2FPT0WU
HSC-4	NX[0fIpFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHPDN4VKSzVyPUi0Ok42OSCwTR?=	NHWw[\|JUSU6JRWK=
QIMR-WIL	MoXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1z6NmlEPTB;OE[yMlA{KG6P	MnPDV2FPT0WU
SW954	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV\seo92UUN3ME24OlMvOTZibl2=	NXTVXJdyW0GQR1XS
HGC-27	NV22elZWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4HicWlEPTB;OEeyMlM1KG6P	NYrTXI5kW0GQR1XS
HH	M3fV[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUji[GhtUUN3ME24PVQvOTJibl2=	NISyPG1USU6JRWK=
KE-37	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\TXpdKSzVyPUi5OE43OiCwTR?=	M2i2[3NCVkeHUh?=
SK-N-DZ	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXfPSJBFUUN3ME25NFAvPDNibl2=	MX7TRW5ITVJ?
J-RT3-T3-5	MnvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NILse5RKSzVyPUmxNE41QSCwTR?=	M{jNS3NCVkeHUh?=
A427	M1TaUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{fKU2lEPTB;OUKwMlg1KG6P	NWLJUZN5W0GQR1XS
ECC10	NX:3RYdQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRTl2NT64O{BvVQ>?	MnLHV2FPT0WU
EW-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXzpNGRXUUN3ME25OFcvOjZibl2=	NVrpPGFrW0GQR1XS
MIA-PaCa-2	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVm1OI9xUUN3ME25OFkvOTJibl2=	M3XMZXNCVkeHUh?=
HCC2218	Mn7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXKPVd[UUN3ME25OVgvPDhibl2=	MVnTRW5ITVJ?
HAL-01	NFTtSYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MonBTWM2OD17NkiuNFQhdk1?	NYrndFQ2W0GQR1XS
RD	NI\BZYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXjnRWh2UUN3ME25O\|QvPDVibl2=	NIjpTWdUSU6JRWK=
SK-N-AS	NFWzR5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIXiXYtKSzVyPUm4PE4yKG6P	MlnBV2FPT0WU
ML-2	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4\wTmlEPTB;MT6wNFQxPyEQvF2=	M1WxeHNCVkeHUh?=
MEL-HO	M4XVOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX\JR\|UxRTFwMEC1PFIh\|ryP	NGq3e2NUSU6JRWK=
MS-1	M3v1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml\qTWM2OD1zLkCwOlE4KM7:TR?=	MVjTRW5ITVJ?
NCI-SNU-1	NVyzelZQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTFwMEKzN\|Eh\|ryP	MX7TRW5ITVJ?
8505C	NYTaOlZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvCVJFKSzVyPUGuNFI{OzFizszN	NUjiW4FzW0GQR1XS
MN-60	NGOz[GhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTFwMEK2PEDPxE1?	M3PxWXNCVkeHUh?=
SAS	NHPVOlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnfRTWM2OD1zLkC0NFgyKM7:TR?=	NVrJVotqW0GQR1XS
EFM-19	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEXkTJdKSzVyPUGuNFQ5PzlizszN	MV\TRW5ITVJ?
Ca9-22	M3TlU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEPBd5dKSzVyPUGuNFUyODdizszN	NFPCdINUSU6JRWK=
NBsusSR	NYLUUJBbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTFwMEWxOlYh\|ryP	M4W2b3NCVkeHUh?=
NB13	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYXDPW91UUN3ME2xMlA2PTBzIN88US=>	NH;4dZdUSU6JRWK=
SF295	MkXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmfTTWM2OD1zLkC2OlI1KM7:TR?=	NX;XSXpUW0GQR1XS
U-2-OS	NW[zOIttT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1jmVmlEPTB;MT6wO\|kyOSEQvF2=	MYjTRW5ITVJ?
NCI-H526	M4DPcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml\kTWM2OD1zLkC4NlkyKM7:TR?=	Mn21V2FPT0WU
KMOE-2	M3P3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTFwMEm0NlIh\|ryP	MlG4V2FPT0WU
RCM-1	MoOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTFwMUKxNFIh\|ryP	MmTlV2FPT0WU
MC116	NVfXU3RzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF3oRZVKSzVyPUGuNVM3OjFizszN	MlrsV2FPT0WU
NCI-H1092	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmnlTWM2OD1zLkG1OFA3KM7:TR?=	NGrSfnFUSU6JRWK=
EW-3	MkS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTFwMUeyNVIh\|ryP	M2PabHNCVkeHUh?=
HCT-116	MoPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGT0R4RKSzVyPUGuNVc4PSEQvF2=	M17o[nNCVkeHUh?=
MC-IXC	M{HiNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYPlRYI{UUN3ME2xMlE4QDhzIN88US=>	NHvUOYZUSU6JRWK=
LB1047-RCC	NUXJ[\|d3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTFwMUizNVIh\|ryP	NVjSUVF6W0GQR1XS
VM-CUB-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEDsfm5KSzVyPUGuNVkyODhizszN	NETGTYhUSU6JRWK=
NB5	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MluwTWM2OD1zLkG5PFU3KM7:TR?=	MX;TRW5ITVJ?
SKG-IIIa	NXG2[po4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYm0S\|BmUUN3ME2xMlI{PDZ2IN88US=>	M4j0UHNCVkeHUh?=
HO-1-N-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{HBR2lEPTB;MT6yN\|g{PSEQvF2=	M4Ta[nNCVkeHUh?=
EFO-27	NWTlfmJUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYPySJdjUUN3ME2xMlI2ODR\|IN88US=>	M3f3[nNCVkeHUh?=
MHH-NB-11	NEPWbW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MonLTWM2OD1zLkK4N\|I6KM7:TR?=	NVzaeWkyW0GQR1XS
SW620	M3mwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTFwMkmwNVgh\|ryP	MnHFV2FPT0WU
MOLT-16	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MknwTWM2OD1zLkK5O\|k4KM7:TR?=	NH:1bYtUSU6JRWK=
NTERA-S-cl-D1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M124VmlEPTB;MT6zNVc3OSEQvF2=	NWTxTXRmW0GQR1XS
VA-ES-BJ	NV63ZYIzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHfLRoNKSzVyPUGuN\|I1PzdizszN	MnfvV2FPT0WU
HCC1419	NWHCc\|VVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTFwM{SwNlch\|ryP	NVy3V4pGW0GQR1XS
NCI-H69	NXXRc\|RvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NI\HXGRKSzVyPUGuN\|QyOTJizszN	NEfUb2tUSU6JRWK=
DEL	M2HxPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIP2bIRKSzVyPUGuN\|UyPjJizszN	NHuw[pNUSU6JRWK=
LXF-289	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTFwM{WyOEDPxE1?	MUjTRW5ITVJ?
EW-11	MnHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX\JR\|UxRTFwM{[wNlYh\|ryP	NYjqZYl1W0GQR1XS
KP-4	Mk[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlLlTWM2OD1zLkO3NFg2KM7:TR?=	MYDTRW5ITVJ?
NOS-1	MoT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnrUTWM2OD1zLkSxNVk1KM7:TR?=	MlzXV2FPT0WU
SK-NEP-1	NF62bFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTFwNEG2PVMh\|ryP	Mn32V2FPT0WU
LAMA-84	NUjnVWhYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVLEb3JzUUN3ME2xMlQ{QTR3IN88US=>	M3PjN3NCVkeHUh?=
ES5	NGrmPYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVXJR\|UxRTFwNESzJO69VQ>?	MXHTRW5ITVJ?
HuO9	MlyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV;JR\|UxRTFwNEWzOlIh\|ryP	NHjGW4JUSU6JRWK=
COLO-684	NYH3dXMyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnvTTWM2OD1zLkS2NVE5KM7:TR?=	MmjBV2FPT0WU
EW-24	NYjmOZNGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{jH[2lEPTB;MT60OlU{OSEQvF2=	MVTTRW5ITVJ?
BV-173	M3\FO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWfJR\|UxRTFwNEeyPVEh\|ryP	MoqzV2FPT0WU
NCI-H1770	NXfUendHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MU\JR\|UxRTFwNEi1N\|Yh\|ryP	NYDqS2pyW0GQR1XS
HuP-T4	NG\ZWJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTFwNEmzJO69VQ>?	M1vjUHNCVkeHUh?=
TYK-nu	NELle5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4fhZ2lEPTB;MT60PVg2OSEQvF2=	MUfTRW5ITVJ?
YH-13	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\NTWM2OD1zLkS5PFk1KM7:TR?=	MUjTRW5ITVJ?
H4	MnXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3lO4VKSzVyPUGuOVA6OTJizszN	M{TpTHNCVkeHUh?=
OVCAR-8	M{TiOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmjDTWM2OD1zLkW0OFc4KM7:TR?=	NHz6enRUSU6JRWK=
NCI-H23	MlG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWT6THI6UUN3ME2xMlU1PjR3IN88US=>	NE\yVXZUSU6JRWK=
ES7	MnGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWTQVGJTUUN3ME2xMlU1Pzd\|IN88US=>	M4GzNXNCVkeHUh?=
COR-L88	NGTkOmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWfvd3Z3UUN3ME2xMlU3PDJ2IN88US=>	MVHTRW5ITVJ?
TI-73	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYfaUHJKUUN3ME2xMlU6ODZizszN	MWTTRW5ITVJ?
RT-112	NVfheZVMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYXHS2dKUUN3ME2xMlU6Ojh2IN88US=>	NIXmd\|JUSU6JRWK=
HuO-3N1	NWjGVolJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXPflh5UUN3ME2xMlU6Ozh3IN88US=>	MX7TRW5ITVJ?
HC-1	M2fSWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF3YSGlKSzVyPUGuOVk5PjZizszN	MYnTRW5ITVJ?
HT55	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVzJR\|UxRTFwNkWxN\|Eh\|ryP	NEi3U45USU6JRWK=
IA-LM	M1\wOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3r6bGlEPTB;MT62PVI4QCEQvF2=	Mn\aV2FPT0WU
EM-2	Mnq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmXWTWM2OD1zLkewNFE1KM7:TR?=	NHfwXIVUSU6JRWK=
MHH-ES-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\tZmFKSzVyPUGuO\|A1OzVizszN	M4m3bXNCVkeHUh?=
CAL-27	Mo[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NES0dYlKSzVyPUGuO\|A3OjFizszN	MUTTRW5ITVJ?
COLO-800	MoLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXXBR2JNUUN3ME2xMlcyOTd7IN88US=>	NVmwUHBQW0GQR1XS
HCE-T	NXHHTWVIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTFwN{G1JO69VQ>?	M2DKTnNCVkeHUh?=
CAMA-1	M2\p[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTFwN{G5O\|Eh\|ryP	NIXJbpFUSU6JRWK=
LOXIMVI	NFL6eZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2nRU2lEPTB;MT63NlEyKM7:TR?=	M2Ky[3NCVkeHUh?=
NH-12	MojiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWHGOYlpUUN3ME2xMlczPjlzIN88US=>	NWP2NoV4W0GQR1XS
TCCSUP	Ml3KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\NO2FKSzVyPUGuO\|I5OjlizszN	NV21SllMW0GQR1XS
MDA-MB-361	NWrvVVlQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHfifHdKSzVyPUGuO\|MyPTdizszN	MnnFV2FPT0WU
EW-16	NXHGRWJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVm5U4N3UUN3ME2xMlc1OTB5IN88US=>	Mmf0V2FPT0WU
SNU-423	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkO2TWM2OD1zLke1PFI4KM7:TR?=	M3TUWHNCVkeHUh?=
Daoy	NGDOTVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkfLTWM2OD1zLke2N\|E6KM7:TR?=	M1jmcnNCVkeHUh?=
ES4	NFP2dFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVe3UGt3UUN3ME2xMlc5PzRzIN88US=>	NELrSVJUSU6JRWK=
PFSK-1	NIPYdmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF62UWJKSzVyPUGuPFA{PyEQvF2=	M1;ucHNCVkeHUh?=
ES3	Ml7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX7JR\|UxRTFwOEK2PFEh\|ryP	NVPJ[Gp4W0GQR1XS
ONS-76	NU\S[Ys2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXLJR\|UxRTFwOEK4PVch\|ryP	M1WyenNCVkeHUh?=
JVM-3	M{Wy[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NY\nfYFWUUN3ME2xMlg2PDVzIN88US=>	NYHkXlhuW0GQR1XS
OS-RC-2	MoX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3PpXmlEPTB;MT64O\|E2OSEQvF2=	MX;TRW5ITVJ?
COLO-320-HSR	NF23Z29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2j4UWlEPTB;MT64PFE6PyEQvF2=	M3;0b3NCVkeHUh?=
HN	NUnpWFNZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTFwOEi3NlUh\|ryP	NH3HS5hUSU6JRWK=
HT	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\1TWM2OD1zLki4PVQ4KM7:TR?=	NUnFbYU4W0GQR1XS
LoVo	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGryWWtKSzVyPUGuPFk5OSEQvF2=	MlO5V2FPT0WU
CGTH-W-1	NGXEW49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX7u[I1zUUN3ME2xMlg6QTR4IN88US=>	MlzzV2FPT0WU
NB6	NIXTPWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1WySWlEPTB;MT65NVI6QCEQvF2=	M4DGcHNCVkeHUh?=
EW-22	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWrQVHlrUUN3ME2xMlkzQDh5IN88US=>	MXzTRW5ITVJ?
ES6	MknZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mmn3TWM2OD1zLkmzOlMyKM7:TR?=	MXTTRW5ITVJ?
SCC-15	NV;lcJVRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXrofoZ7UUN3ME2xMlk{QDF7IN88US=>	MoHRV2FPT0WU
HL-60	M2ewfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnK2TWM2OD1zLkmzPVAzKM7:TR?=	NF;tVJlUSU6JRWK=
human HOP-92	NV;VZ3dnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWnyTYJXUUN3ME2xMlk1ODZ3IN88US=>	NFe4ZXZUSU6JRWK=
SW626	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NI\PWFdKSzVyPUGuPVQ5QTlizszN	MYXTRW5ITVJ?
HEC-1	NYixXYNbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTFwOUWzOkDPxE1?	NWjQZoZsW0GQR1XS
LB2241-RCC	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{jvS2lEPTB;MT65PFI{OSEQvF2=	MXzTRW5ITVJ?
Ramos-2G6-4C10	M{\ofmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4nVSmlEPTB;MT65PVQ6OyEQvF2=	NH7vToVUSU6JRWK=
A101D	MkHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3z0bGlEPTB;Mj6yNFMxOyEQvF2=	NFfsOVNUSU6JRWK=
NCI-H446	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn61TWM2OD1{LkC0OVk6KM7:TR?=	NELRfINUSU6JRWK=
SBC-5	NV3BT2FXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2O5V2lEPTB;Mj6wOlE1PyEQvF2=	M2LiTHNCVkeHUh?=
HOS	NWDwdG9GT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFP0emZKSzVyPUKuNFc3PTNizszN	MUnTRW5ITVJ?
K5	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml:4TWM2OD1{LkC3PFEyKM7:TR?=	NEjBTmJUSU6JRWK=
HLE	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGrVPHhKSzVyPUKuNFg2OjlizszN	M2jsWHNCVkeHUh?=
HSC-2	Mmq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoTMTWM2OD1{LkGyPFk5KM7:TR?=	M33DWnNCVkeHUh?=
LCLC-97TM1	NW\hO2lTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTJwMUS1PFMh\|ryP	NUjwR4NxW0GQR1XS
DMS-273	NVrTdJk6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTJwMUS4N\|ch\|ryP	NFvGRo1USU6JRWK=
TE-8	MmjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4H0UGlEPTB;Mj6xOVc3PSEQvF2=	M1nIbnNCVkeHUh?=
DSH1	NYHKVFR6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn3OTWM2OD1{LkG2N\|k5KM7:TR?=	MmjwV2FPT0WU
CAL-51	NGfQcFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGnDZ\|VKSzVyPUKuNVY3QTlizszN	M4\jZ3NCVkeHUh?=
IST-SL1	MmDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmTWTWM2OD1{LkG2PFQ1KM7:TR?=	M2iyXnNCVkeHUh?=
GCT	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFf2NoZKSzVyPUKuNVc4PyEQvF2=	NGS0eINUSU6JRWK=
SW948	NEC5[llIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUnDS4FbUUN3ME2yMlE5PDV4IN88US=>	NVXPTVF7W0GQR1XS
NOMO-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXf2OmYyUUN3ME2yMlE6OzF5IN88US=>	NFfBbllUSU6JRWK=
C8166	MofZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml\XTWM2OD1{LkKxN\|M1KM7:TR?=	MmDvV2FPT0WU
OC-314	NFrqUodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{C3PWlEPTB;Mj6yN\|I2QSEQvF2=	NXPBV2xGW0GQR1XS
CAL-39	NETnTm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NELlbXRKSzVyPUKuNlM3OjZizszN	NV3nS4xWW0GQR1XS
MDA-MB-453	NXXCd2w{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTJwMkSyO\|Uh\|ryP	Mn7XV2FPT0WU
A673	NInHb\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4jycWlEPTB;Mj6yOVg3OiEQvF2=	M2fxXXNCVkeHUh?=
HTC-C3	M1PvVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MluzTWM2OD1{LkK2PFUh\|ryP	M4TUNnNCVkeHUh?=
NCI-H1666	NHey[W1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnu3TWM2OD1{LkK4NVEyKM7:TR?=	NVjDc\|NVW0GQR1XS
PSN1	NHrQcYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml[1TWM2OD1{LkK4PVE{KM7:TR?=	MVjTRW5ITVJ?
GI-1	NWjkcoVZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\JTWM2OD1{LkOwOVQ{KM7:TR?=	NHTqcZlUSU6JRWK=
HuH-7	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4D2ZmlEPTB;Mj6zNFY{PyEQvF2=	NWDtRW1qW0GQR1XS
JAR	M2TITWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{njR2lEPTB;Mj6zNVk5PyEQvF2=	NVzme\|Q3W0GQR1XS
5637	M2fLN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHXqUG5KSzVyPUKuN\|IyOjlizszN	MkLFV2FPT0WU
GB-1	M3i5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3vtOmlEPTB;Mj6zNlM{PSEQvF2=	M2PYdXNCVkeHUh?=
KP-N-YS	MlvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmSwTWM2OD1{LkOyOlE2KM7:TR?=	NIjtd\|lUSU6JRWK=
OAW-42	M17Iemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYXlNmNiUUN3ME2yMlM{PDF4IN88US=>	NWT5PWdxW0GQR1XS
8-MG-BA	NGfLc5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1LqOWlEPTB;Mj6zN\|kxPiEQvF2=	Ml3ZV2FPT0WU
RH-18	M2LCemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWTESmliUUN3ME2yMlM2ODJ{IN88US=>	M2m0UHNCVkeHUh?=
NCI-H1155	M{Plc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvzUIdKSzVyPUKuN\|Y4OjVizszN	MWjTRW5ITVJ?
NB17	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnjFTWM2OD1{LkO4NlQ{KM7:TR?=	M1jsUHNCVkeHUh?=
NCI-H1437	NWizb2Z6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRTJwNEG4O\|Mh\|ryP	MmCxV2FPT0WU
SN12C	NU\jRlh{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\1TWM2OD1{LkSzNlE1KM7:TR?=	NUfsSGZ3W0GQR1XS
HSC-3	NFi4RZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTJwNES1NFkh\|ryP	NWqydWxlW0GQR1XS
GAMG	NUL4OFdST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEO3SlNKSzVyPUKuOFQ2PjFizszN	M3zRbnNCVkeHUh?=
HT-1080	NHTKdYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTJwNES4OlQh\|ryP	NIfFRZhUSU6JRWK=
A549	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWSzSpB[UUN3ME2yMlQ1QDl\|IN88US=>	MVrTRW5ITVJ?
KNS-62	NVXCPHpkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYXJR\|UxRTJwNEWwOlEh\|ryP	NHOyOllUSU6JRWK=
YKG-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1K5R2lEPTB;Mj60OVQ{PyEQvF2=	MoDqV2FPT0WU
LU-134-A	NU\sWWliT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTJwNEewNFgh\|ryP	M1PVU3NCVkeHUh?=
FADU	MljQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUC5[nJpUUN3ME2yMlQ4OTZ{IN88US=>	NXPMVXNqW0GQR1XS
TGBC11TKB	NGjlfZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWLh[\|l1UUN3ME2yMlQ4OTd5IN88US=>	MX\TRW5ITVJ?
HT-3	NYPpZ5VUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3rjS2lEPTB;Mj60PVU{PSEQvF2=	M1HPfnNCVkeHUh?=
NCI-H2170	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4jWXmlEPTB;Mj61NFU1QSEQvF2=	M{SyRnNCVkeHUh?=
Mo-T	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MknwTWM2OD1{LkWwPVI4KM7:TR?=	M3vtW3NCVkeHUh?=
CCRF-CEM	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTJwNUOwOFMh\|ryP	M4PKTHNCVkeHUh?=
KU-19-19	M{HBNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTJwNUO1NVMh\|ryP	NYn2XmtiW0GQR1XS
NCI-H1048	M375V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXudXZKSzVyPUKuOVUxOjVizszN	MW\TRW5ITVJ?
KOSC-2	NH25UlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3S3NWlEPTB;Mj61OlA4PiEQvF2=	NV\H[3U2W0GQR1XS
A431	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3v4PWlEPTB;Mj61OlM{PSEQvF2=	NHTHUW9USU6JRWK=
COR-L23	NGmyeFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFXzd49KSzVyPUKuOVg2PjZizszN	NXK1PWoyW0GQR1XS
MKN28	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXvJR\|UxRTJwNUmwN\|ch\|ryP	MmHwV2FPT0WU
22RV1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTJwNUmyO\|Qh\|ryP	M37FU3NCVkeHUh?=
ABC-1	M2nFeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3T4cmlEPTB;Mj62NFQ3KM7:TR?=	NGTvU\|JUSU6JRWK=
NCI-H2126	NWfUdGd4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{LF[WlEPTB;Mj62NFk5PCEQvF2=	NUjndFA6W0GQR1XS
DoTc2-4510	MnjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1j2U2lEPTB;Mj62NlE5PSEQvF2=	NX3Xc5lPW0GQR1XS
SCC-4	NY[4eFFQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTJwNkOwNVIh\|ryP	Moq4V2FPT0WU
NCI-H661	NF3PZVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1fvSWlEPTB;Mj62OFA5PSEQvF2=	M1fBTnNCVkeHUh?=
RPMI-2650	NFLUT4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIm1OW5KSzVyPUKuOlQyPDNizszN	NHvyRWRUSU6JRWK=
NCI-H510A	Ml7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXLJR\|UxRTJwNkS0NlYh\|ryP	NYW1OphCW0GQR1XS
BPH-1	M3fafmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHyydXVKSzVyPUKuOlU5PSEQvF2=	MkX2V2FPT0WU
M14	M3iycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF65WVVKSzVyPUKuOlY6QTNizszN	MmrtV2FPT0WU
G-402	M{HOfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2TsbWlEPTB;Mj63NFQ2OSEQvF2=	NITST3lUSU6JRWK=
AsPC-1	NVvGe5FPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmLUTWM2OD1{LkexNVch\|ryP	M{T2c3NCVkeHUh?=
NB12	M333Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3zD[2lEPTB;Mj63NVcyKM7:TR?=	MUjTRW5ITVJ?
SK-HEP-1	NUPSPWZCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX7YWFRiUUN3ME2yMlc1OzlzIN88US=>	MknNV2FPT0WU
U-266	MlPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUHlXmtOUUN3ME2yMlc4OTJzIN88US=>	M2n2NXNCVkeHUh?=
AM-38	NHPIe45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRTJwN{ezOVUh\|ryP	MWXTRW5ITVJ?
PC-14	NEHhbnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXHJR\|UxRTJwOEC1NUDPxE1?	NUj5TpZ5W0GQR1XS
EGI-1	NXPadoVqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTJwOEG3OFMh\|ryP	NWmwZ5hOW0GQR1XS
LS-411N	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHHXbGpKSzVyPUKuPFI{OyEQvF2=	NYHpN5JzW0GQR1XS
BFTC-905	NFTEWHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{XUUmlEPTB;Mj64OVUzOyEQvF2=	NFjRU3hUSU6JRWK=
CaR-1	MomwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWjndppuUUN3ME2yMlg3KM7:TR?=	MlHEV2FPT0WU
NCI-H292	Mne3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTJwOE[1PVYh\|ryP	NXLEPXp6W0GQR1XS
8305C	MkLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRTJwOE[2OFUh\|ryP	M3KxZnNCVkeHUh?=
SNU-449	NGTMc4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWmxbYF{UUN3ME2yMlg6OTh{IN88US=>	NFXleZVUSU6JRWK=
LCLC-103H	NGjWbJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTJwOUC0N\|gh\|ryP	MkPKV2FPT0WU
SW1573	MkXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF\Fd5ZKSzVyPUKuPVYxQDJizszN	NGnTRpJUSU6JRWK=
MLMA	M{n5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYfGOmtSUUN3ME2yMlk3PzF5IN88US=>	M2XRd3NCVkeHUh?=
NCI-H1355	Mle4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{XWPGlEPTB;Mz6wNFc6PiEQvF2=	NHLTNY1USU6JRWK=
RMG-I	M1XleGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGDNVm9KSzVyPUOuNFI2QTJizszN	Mnv4V2FPT0WU
BB65-RCC	M{[2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYHJR\|UxRTNwMEOzNVQh\|ryP	NGDxXIRUSU6JRWK=
PC-3	NEHJVXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTNwMEO4O\|Qh\|ryP	Ml3xV2FPT0WU
SF268	NVXDPYJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NELLboZKSzVyPUOuNFQ2OjNizszN	Ml7nV2FPT0WU
NCI-H810	M361PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHL0b5RKSzVyPUOuNFQ5OjNizszN	NWDScZB3W0GQR1XS
MEG-01	NVXwc3RYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRTNwME[xOlQh\|ryP	NUPjNlB3W0GQR1XS
SW13	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXvJR\|UxRTNwMEe4OFch\|ryP	MVTTRW5ITVJ?
RH-1	NHLXVYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYW4TWIxUUN3ME2zMlExOjd6IN88US=>	MVrTRW5ITVJ?
GT3TKB	NUfm[JFnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWracJI1UUN3ME2zMlEyOjh\|IN88US=>	M2DvcHNCVkeHUh?=
TK10	M4fXOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHPVU\|dKSzVyPUOuNVM4OjRizszN	NX30NpJsW0GQR1XS
T-24	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4KyfmlEPTB;Mz6xOVA4KM7:TR?=	MXXTRW5ITVJ?
A498	MoSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4XvcWlEPTB;Mz6yNFg4OSEQvF2=	NGPsPVFUSU6JRWK=
GR-ST	M1u1Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3XsNWlEPTB;Mz6yNlE{QSEQvF2=	MkD0V2FPT0WU
LB2518-MEL	M1\EO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXLTOmR[UUN3ME2zMlIzOzl6IN88US=>	Mmf6V2FPT0WU
T47D	NVLlSlJmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH31PHhKSzVyPUOuNlM3OjdizszN	NH;5WWdUSU6JRWK=
NCI-H1651	NIfSb\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\jSWFKSzVyPUOuNlQ3PDRizszN	MWHTRW5ITVJ?
EC-GI-10	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYD0UFdQUUN3ME2zMlI3OTV\|IN88US=>	NEO5eldUSU6JRWK=
HT-29	MkfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYi1eXdLUUN3ME2zMlI3PjF2IN88US=>	M2XPO3NCVkeHUh?=
GI-ME-N	NUn1c3lzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYLybIROUUN3ME2zMlI6PTFzIN88US=>	Mnz4V2FPT0WU
SW756	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTNwMkm2Nlkh\|ryP	MmLtV2FPT0WU
RKO	NFnNN2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIXTbHpKSzVyPUOuN\|A4PTdizszN	MUfTRW5ITVJ?
NCI-H1563	NUDVUlllT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHn0c2NKSzVyPUOuN\|MxOThizszN	NHfqe25USU6JRWK=
DJM-1	NYXCTHJVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTNwM{e2O\|Qh\|ryP	MYXTRW5ITVJ?
L-428	NG\aWYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NITwXmFKSzVyPUOuOFAxPDVizszN	NIi0NllUSU6JRWK=
NCI-H2122	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGH3OpBKSzVyPUOuOFE{OTJizszN	NIH5WVJUSU6JRWK=
Ca-Ski	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2HxRWlEPTB;Mz60OVQ{KM7:TR?=	MXLTRW5ITVJ?
639-V	NUexSWx7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MljJTWM2OD1\|LkS2NFU4KM7:TR?=	NYXpOllyW0GQR1XS
SW1116	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\CPI9qUUN3ME2zMlQ3OjZ7IN88US=>	Mmn6V2FPT0WU
DMS-114	M{fkdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4WxVmlEPTB;Mz60O\|A3PiEQvF2=	NXfQbIZWW0GQR1XS
MZ2-MEL	NV;kVnFjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3PmfmlEPTB;Mz60O\|Y5OSEQvF2=	MUTTRW5ITVJ?
COLO-829	NGPzfJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWTmUIdbUUN3ME2zMlUxODd\|IN88US=>	M{LYVnNCVkeHUh?=
J82	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGPCUphKSzVyPUOuOVA2PyEQvF2=	MVvTRW5ITVJ?
EW-13	M4\VcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWHX[pQ{UUN3ME2zMlUzPTFizszN	MVLTRW5ITVJ?
RXF393	MmO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUntR3B4UUN3ME2zMlU{Ojl2IN88US=>	NGjETZdUSU6JRWK=
CAL-62	M2n1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUPJR\|UxRTNwNUS1NVQh\|ryP	MVPTRW5ITVJ?
OCUB-M	NW[2UllrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTNwNUS2OlUh\|ryP	NEO1UJpUSU6JRWK=
BT-474	NFXLWZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVzRRZN4UUN3ME2zMlY{OzFizszN	MkDHV2FPT0WU
KYSE-180	MkXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGi1[GNKSzVyPUOuOlM{PzJizszN	NGjCcYVUSU6JRWK=
NCI-H650	Mo\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NECxVXlKSzVyPUOuOlQzQDdizszN	MYjTRW5ITVJ?
Detroit562	Mo[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NG[y[45KSzVyPUOuOlUxOjJizszN	M2Xze3NCVkeHUh?=
SW48	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH;YOXNKSzVyPUOuOlU3PTdizszN	MlLIV2FPT0WU
KYSE-450	NX3OTnhHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmHmTWM2OD1\|Lk[4OVgzKM7:TR?=	NGTteZVUSU6JRWK=
KYSE-510	MlvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4PtTWlEPTB;Mz63NlE5OSEQvF2=	MXzTRW5ITVJ?
GP5d	M{fqdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlSxTWM2OD1\|LkeyPVUh\|ryP	NVnwNmQ{W0GQR1XS
RPMI-7951	M1LzTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYrCdYpCUUN3ME2zMlc1PzJ\|IN88US=>	NFLyVINUSU6JRWK=
Becker	M{f2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MonoTWM2OD1\|Lke1NFEzKM7:TR?=	M2G1eXNCVkeHUh?=
WM-115	M3;WdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXqS5pKSzVyPUOuO\|gyQTVizszN	M3vnNXNCVkeHUh?=
G-401	NIDudXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFjD[\|JKSzVyPUOuO\|kxQDVizszN	MVrTRW5ITVJ?
PANC-08-13	NYnFe4JqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHXZXmlKSzVyPUOuO\|k3ODJizszN	NF3KSZBUSU6JRWK=
SW982	NVnhcml{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3i4WmlEPTB;Mz64NFU2OSEQvF2=	MX3TRW5ITVJ?
D-263MG	MkPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWq2UZBnUUN3ME2zMlgzODVzIN88US=>	NU\kSno3W0GQR1XS
KM-H2	NIDlOoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEDnb3BKSzVyPUOuPFI3OjRizszN	MnO2V2FPT0WU
SK-MEL-3	MnnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnuS25KSzVyPUOuPFI5PDFizszN	Mly3V2FPT0WU
NCI-H1581	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4\kNmlEPTB;Mz64OFQ5QCEQvF2=	M3LaTXNCVkeHUh?=
LS-123	MlHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1H0S2lEPTB;Mz64O\|kxQSEQvF2=	NFPxS2RUSU6JRWK=
CAKI-1	MkTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnLtTWM2OD1\|Lki5NFUzKM7:TR?=	MXvTRW5ITVJ?
MEL-JUSO	MmnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{WxXmlEPTB;Mz64PVE2OyEQvF2=	M2DXNnNCVkeHUh?=
HCE-4	M1XIWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3zyZmlEPTB;Mz65NVY3OyEQvF2=	NX3LWHZIW0GQR1XS
TE-10	NF3FUXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTNwOUKwNUDPxE1?	NFXQdXBUSU6JRWK=
OVCAR-4	NX30fZM5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUfJR\|UxRTNwOUK4PFkh\|ryP	M1f3RnNCVkeHUh?=
ETK-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlfOTWM2OD1\|Lkm0OlM2KM7:TR?=	M4Dr[3NCVkeHUh?=
A2780	M1fGeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml3xTWM2OD12LkC1PVY3KM7:TR?=	MYrTRW5ITVJ?
LU-65	MofVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGDDRmRKSzVyPUSuNFc3OzNizszN	M{T1d3NCVkeHUh?=
BHY	NWGyNGpvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGPMe\|dKSzVyPUSuNVI1QTVizszN	MYnTRW5ITVJ?
COR-L105	Mn;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYeyc\|dKUUN3ME20MlE{ODVzIN88US=>	MXTTRW5ITVJ?
CAL-12T	M4DqdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUSzPVQ3UUN3ME20MlE{OTB\|IN88US=>	MWXTRW5ITVJ?
SCH	NWHmdIU3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUPOdJJxUUN3ME20MlE2PzR\|IN88US=>	MWDTRW5ITVJ?
CW-2	MonYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHjUfpNKSzVyPUSuNVkxODFizszN	MUDTRW5ITVJ?
HCC1806	M{\6bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWnRO4hDUUN3ME20MlIxOzF{IN88US=>	NGfSTYtUSU6JRWK=
KP-N-YN	Moj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXzlW\|U2UUN3ME20MlIxQTJ5IN88US=>	M1;uNXNCVkeHUh?=
T98G	NILYR21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnrZTWM2OD12LkKyNVU4KM7:TR?=	M2TpdnNCVkeHUh?=
CAL-54	Mn71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3jFZmlEPTB;ND6yNlM5OSEQvF2=	NX7JT4djW0GQR1XS
CAL-33	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{\LfmlEPTB;ND6yN\|A3PCEQvF2=	MXrTRW5ITVJ?
SNU-C2B	NVLKclRvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWTifY5zUUN3ME20MlI1PzZ7IN88US=>	NVzW[ow5W0GQR1XS
NUGC-3	NIS2TJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M33JS2lEPTB;ND6yOVUxPSEQvF2=	M{H3SXNCVkeHUh?=
DOK	MnzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV;LXpN[UUN3ME20MlI3PTl\|IN88US=>	NXPIelJUW0GQR1XS
MMAC-SF	NH23RplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mlu2TWM2OD12LkK2PFU6KM7:TR?=	Mkn3V2FPT0WU
KYSE-70	Mnq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWO1PGQ2UUN3ME20MlI6OzRizszN	MYfTRW5ITVJ?
A204	NVjsNIM6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVeyflZPUUN3ME20MlM2QDB\|IN88US=>	NV;s[IloW0GQR1XS
SCC-25	NV72SXRQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGrrZlNKSzVyPUSuN\|U5OTlizszN	NWDiNGxWW0GQR1XS
EPLC-272H	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mlz3TWM2OD12LkO4PVUh\|ryP	M3\hcnNCVkeHUh?=
CAL-120	NGDUVnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTRwM{i5PVIh\|ryP	M1PRT3NCVkeHUh?=
LS-513	M{Wzb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTRwNEKxPVgh\|ryP	Mn7wV2FPT0WU
CAPAN-1	NXHn[4cxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV;M[IdSUUN3ME20MlQzOzh{IN88US=>	NIDB[odUSU6JRWK=
ESS-1	MoX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYLJR\|UxRTRwNEK3NlQh\|ryP	M4rrZnNCVkeHUh?=
GMS-10	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml:0TWM2OD12LkSyPFE6KM7:TR?=	NWTVUGZ5W0GQR1XS
NCI-N87	Mn2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIXNNnhKSzVyPUSuOVA5PjhizszN	MnmzV2FPT0WU
HMV-II	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGL5bJJKSzVyPUSuOVE4OyEQvF2=	MnW5V2FPT0WU
COLO-741	M{jxd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MomwTWM2OD12LkW1PVk1KM7:TR?=	NHjNeGlUSU6JRWK=
MKN45	NIrBXmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIPJT41KSzVyPUSuOVc4OzJizszN	NWK3VpFDW0GQR1XS
OAW-28	NEnnZY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoOzTWM2OD12LkW4N\|k5KM7:TR?=	MXzTRW5ITVJ?
OCI-AML2	NH61eZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoXMTWM2OD12Lk[1NlM5KM7:TR?=	NIflXWNUSU6JRWK=
MDA-MB-231	MlHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIL1blRKSzVyPUSuO\|AzPDNizszN	M{G4VHNCVkeHUh?=
NCI-H1648	Ml;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXPJR\|UxRTRwN{KyO\|Mh\|ryP	NUTRfIlsW0GQR1XS
NCI-H1792	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIW0WmJKSzVyPUSuO\|YyODdizszN	NV\VVpVVW0GQR1XS
GCIY	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFjXfIxKSzVyPUSuO\|c1OjRizszN	M3;iUnNCVkeHUh?=
Hs-578-T	M1rjU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGi1c\|FKSzVyPUSuO\|c3PTVizszN	MYfTRW5ITVJ?
SW962	MlW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlzKTWM2OD12Lke4NFEyKM7:TR?=	MV7TRW5ITVJ?
NCI-H630	NYXXWGV3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M17CW2lEPTB;ND63PFA5OSEQvF2=	MX7TRW5ITVJ?
786-0	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2rIcGlEPTB;ND63PFc4OyEQvF2=	M1nIb3NCVkeHUh?=
FTC-133	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M123fmlEPTB;ND63PVI3OyEQvF2=	M1PN[3NCVkeHUh?=
BT-20	NV21OJdQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVf0VGZGUUN3ME20Mlc6PDJ7IN88US=>	MXTTRW5ITVJ?
Mewo	Mlz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXKUZcxUUN3ME20MlgyPzR5IN88US=>	MoDXV2FPT0WU
SW780	Mn;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn\XTWM2OD12Lki1O\|Y3KM7:TR?=	M17mPHNCVkeHUh?=
OE33	M3fPe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFfURZJKSzVyPUSuPFc4OTNizszN	MU\TRW5ITVJ?
HCC1569	M2PBRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTRwOEi0OVgh\|ryP	MmO0V2FPT0WU
TE-6	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVzJR\|UxRTRwOUO5O\|ch\|ryP	M4W2TXNCVkeHUh?=
SK-N-FI	NF3kOWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFyyWIlKSzVyPUSuPVQ1OjFizszN	MV3TRW5ITVJ?
PANC-03-27	NXmySpVYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmPoTWM2OD12Lkm5PVYzKM7:TR?=	NWrzNZV1W0GQR1XS
MCF7	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\HRohKSzVyPUWuNFA4OzhizszN	NUfOZXR2W0GQR1XS
UACC-257	M1zuTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUfSW2RbUUN3ME21MlAzQDR3IN88US=>	NVrTV5hvW0GQR1XS
SW1088	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{PXOWlEPTB;NT6wNlk1PCEQvF2=	MYjTRW5ITVJ?
A704	MnnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1LUZWlEPTB;NT6wN\|A3KM7:TR?=	MWLTRW5ITVJ?
A2058	MmrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWLQZ2pkUUN3ME21MlA2QTB6IN88US=>	NGPsO2FUSU6JRWK=
Calu-3	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEPxVo9KSzVyPUWuNFY1PTJizszN	M2PPNHNCVkeHUh?=
RERF-LC-MS	MmHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWfJR\|UxRTVwME[5NFMh\|ryP	NGLiS5ZUSU6JRWK=
AU565	M{TVT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTVwMEm3NFIh\|ryP	M{LyfXNCVkeHUh?=
DMS-79	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFnVTWxKSzVyPUWuNVM5QDNizszN	NWXDb2VHW0GQR1XS
DK-MG	Mlf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{XNU2lEPTB;NT6xPFQ{QCEQvF2=	MXnTRW5ITVJ?
HuCCT1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2ezeGlEPTB;NT6yN\|g2PiEQvF2=	NFOzWmpUSU6JRWK=
HT-144	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkXkTWM2OD13LkK0PVg4KM7:TR?=	M1PiNHNCVkeHUh?=
M059J	NIjGd\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml63TWM2OD13LkK1O\|Yh\|ryP	MYLTRW5ITVJ?
COLO-792	MlHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4TL[2lEPTB;NT6yOlM2PiEQvF2=	M4i5bHNCVkeHUh?=
SF539	M2jtRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTVwMk[2N\|Ih\|ryP	MkPtV2FPT0WU
SK-UT-1	M2jQdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoHZTWM2OD13LkK3O\|UyKM7:TR?=	NVHpfZBYW0GQR1XS
NCI-H1703	NIjLcJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4fRSGlEPTB;NT6zOVgzPiEQvF2=	MmnOV2FPT0WU
SW837	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4HLcGlEPTB;NT6zO\|g4QCEQvF2=	NXXqU3lMW0GQR1XS
U251	MkTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NY[1XGluUUN3ME21MlM6ODl4IN88US=>	M4XnVXNCVkeHUh?=
SW1710	MlL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTVwNEG1OVQh\|ryP	MYDTRW5ITVJ?
NCI-H1299	NXj5c\|NkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGHjOW5KSzVyPUWuOFY{OzVizszN	NYPScnhjW0GQR1XS
RVH-421	NXr4bFd{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFi4fFhKSzVyPUWuOFk6ODhizszN	NH3WOmlUSU6JRWK=
UM-UC-3	MmexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX7JR\|UxRTVwNkK2OVEh\|ryP	M1fXRnNCVkeHUh?=
MDA-MB-175-VII	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlHwTWM2OD13Lk[0NFQyKM7:TR?=	MYLTRW5ITVJ?
KYSE-270	M4rjT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF3SemdKSzVyPUWuOlYxOzFizszN	NVvHd4N7W0GQR1XS
COLO-668	NXTXU3VST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkC5TWM2OD13LkexN\|Ih\|ryP	Mn7NV2FPT0WU
LN-405	MnTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH;MZYhKSzVyPUWuO\|MxQDVizszN	MV3TRW5ITVJ?
HT-1376	M37Xfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4DrfmlEPTB;NT63PFA2OiEQvF2=	NVvxUmlZW0GQR1XS
769-P	M3jafmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NY[5cpJFUUN3ME21Mlg3PzF6IN88US=>	NUfjcJNXW0GQR1XS
HuP-T3	NEWyd4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MknrTWM2OD13Lki4Olc4KM7:TR?=	M2\OWXNCVkeHUh?=
MDA-MB-415	M2\leGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIDyTIdKSzVyPUWuPVIyOzlizszN	MYHTRW5ITVJ?
MKN7	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTVwOUi4JO69VQ>?	MVrTRW5ITVJ?
KS-1	M3XMR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkXYTWM2OD13Lkm4PFM3KM7:TR?=	M1;UTnNCVkeHUh?=
647-V	M1y5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;jOFhKSzVyPUWuPVkyPDhizszN	MXvTRW5ITVJ?
COLO-679	NEWyb41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHnJO\|FKSzVyPU[uNFAzPTVizszN	Mly1V2FPT0WU
AN3-CA	NV\VdnB{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NY\LOmRIUUN3ME22MlA{PDRzIN88US=>	NGexdG5USU6JRWK=
C32	M{[0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2nCb2lEPTB;Nj6xN\|A{PCEQvF2=	NWDINFVpW0GQR1XS
KM12	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWTJR\|UxRTZwMkSwPVkh\|ryP	NUjxXGZLW0GQR1XS
KINGS-1	MmTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn6wTWM2OD14LkK2NVUzKM7:TR?=	NETqTJNUSU6JRWK=
KYSE-410	NVrsVopqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWqxdXdrUUN3ME22MlMxPjR3IN88US=>	NIPoTHZUSU6JRWK=
HPAF-II	NYLlU3pGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NG\5Om1KSzVyPU[uN\|U1QCEQvF2=	MlfYV2FPT0WU
LAN-6	M3\mdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV6yN2VQUUN3ME22MlQ6PjNzIN88US=>	M4TCSXNCVkeHUh?=
LU-99A	Mk[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4D5PGlEPTB;Nj61OVk5QSEQvF2=	MVLTRW5ITVJ?
SJSA-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4rKN2lEPTB;Nj61OlM1PyEQvF2=	M2LXVHNCVkeHUh?=
MSTO-211H	M4L2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHnnfphKSzVyPU[uO\|IzOzNizszN	M2fufnNCVkeHUh?=
SW900	MlHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXHJR\|UxRTZwN{[yNlEh\|ryP	NEC3OlhUSU6JRWK=
LNCaP-Clone-FGC	NGSzd2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlfLTWM2OD14LkiwOFA{KM7:TR?=	MVvTRW5ITVJ?
OMC-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3qz[mlEPTB;Nj64OVQxOiEQvF2=	MXrTRW5ITVJ?
IST-MEL1	MkfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTZwOEm2Olkh\|ryP	NETMbmhUSU6JRWK=
TE-9	M2j1Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3T5fWlEPTB;Nj64PVg1PyEQvF2=	NYHJ[nhRW0GQR1XS
NCI-H2030	MmfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEfNR3dKSzVyPU[uPVEzOjZizszN	MWLTRW5ITVJ?
BFTC-909	MkfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{f3[WlEPTB;Nz6wNFY1OSEQvF2=	M37aWHNCVkeHUh?=
NCI-SNU-5	MoDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV7JR\|UxRTdwMEKxOVkh\|ryP	Mk\3V2FPT0WU
TE-5	M{D1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml7aTWM2OD15LkCyPFgyKM7:TR?=	M1nYXHNCVkeHUh?=
SK-MES-1	NEHHZmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoG3TWM2OD15LkC1OFI4KM7:TR?=	NFnUeo1USU6JRWK=
SHP-77	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnzlTWM2OD15LkGzPVUzKM7:TR?=	M3zLenNCVkeHUh?=
NCI-H1623	NXPUPJFLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFLwV3VKSzVyPUeuNVQxPzJizszN	NV3iVmJrW0GQR1XS
TE-11	M4q5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MonuTWM2OD15LkG1NVg1KM7:TR?=	M2fyO3NCVkeHUh?=
EKVX	NHWyPXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF;0R4hKSzVyPUeuNVkzPjdizszN	M33hS3NCVkeHUh?=
OVCAR-3	NGSzVIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MknmTWM2OD15LkKxNVM{KM7:TR?=	Mk[1V2FPT0WU
C3A	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXvJR\|UxRTdwM{S1NkDPxE1?	M{LYVnNCVkeHUh?=
CFPAC-1	NIewe2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M17BbWlEPTB;Nz6zOlIzOiEQvF2=	NUHiSIFSW0GQR1XS
MG-63	NYrEO5ZLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVf1XYNsUUN3ME23MlQyQDR7IN88US=>	MoHVV2FPT0WU
KYSE-140	NFjxW3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTdwNESwOlEh\|ryP	NXzaSoM1W0GQR1XS
MPP-89	NHnJ[o9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnf5TWM2OD15LkW5O\|I6KM7:TR?=	M1nE[HNCVkeHUh?=
COLO-824	M4G2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1u1UWlEPTB;Nz63Nlg3OyEQvF2=	NHjXbZlUSU6JRWK=
SiHa	MmHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFrBVo1KSzVyPUeuPFM4ODdizszN	M4HRbXNCVkeHUh?=
SNU-387	NHjLVVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\VOm5KSzVyPUeuPFU{PDdizszN	NGC1fXhUSU6JRWK=
A172	M4TUemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mmm5TWM2OD15Lki2NVczKM7:TR?=	MWjTRW5ITVJ?
COLO-680N	MmHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW\HNJZqUUN3ME23MlkyPzNizszN	MmSwV2FPT0WU
HCC1395	M1XPfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1\uNmlEPTB;OD6wOVQ2OiEQvF2=	NXfL[3hvW0GQR1XS
NCI-H28	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnnKTWM2OD16LkC1PVY{KM7:TR?=	NGLBbWVUSU6JRWK=
LC-2-ad	MkfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{DS[2lEPTB;OD6yNVk{PyEQvF2=	M2XNdXNCVkeHUh?=
S-117	NIjwbmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEDWTmNKSzVyPUiuNlU{PTNizszN	MWPTRW5ITVJ?
NCI-H1838	Mk\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXrV[INwUUN3ME24MlI2PzhzIN88US=>	NXraXIpEW0GQR1XS
PANC-10-05	NGjQZoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEfjc4pKSzVyPUiuN\|cxPDdizszN	NELISlJUSU6JRWK=
KALS-1	NU\lR297T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkHxTWM2OD16LkWwPVI5KM7:TR?=	NULZOHVqW0GQR1XS
LS-1034	NX2xfHF6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVe4b\|JrUUN3ME24MlU4PDN5IN88US=>	NGjHNVVUSU6JRWK=
TGBC1TKB	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3jrOWlEPTB;OD63N\|U{PSEQvF2=	MlKwV2FPT0WU
OE19	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkD4TWM2OD16Lke2NlYzKM7:TR?=	M1PwfXNCVkeHUh?=
D-502MG	M1\Ybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHHvWpBKSzVyPUiuO\|Y6QTRizszN	MYrTRW5ITVJ?
JEG-3	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYXJR\|UxRThwN{i2NVgh\|ryP	MlrJV2FPT0WU
DBTRG-05MG	M37jeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mmr3TWM2OD16Lki3OVY2KM7:TR?=	M4[yT3NCVkeHUh?=
ME-180	M3vhU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MojNTWM2OD17LkC2O\|I2KM7:TR?=	NF[wW3pUSU6JRWK=
NCI-H1573	NUTtenZJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTlwMUC1N\|Ih\|ryP	NEHUNI5USU6JRWK=
HCC2998	Mki4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnK0TWM2OD17LkGzOlgyKM7:TR?=	NGPVTlhUSU6JRWK=
ACHN	M2H2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mk[zTWM2OD17LkK0PVc2KM7:TR?=	M1fVU3NCVkeHUh?=
D-392MG	M3naOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGP5eWdKSzVyPUmuNlU4OTVizszN	M{PFTXNCVkeHUh?=
no-11	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTlwMk[wNlgh\|ryP	MUXTRW5ITVJ?
KLE	Ml3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4CxZWlEPTB;OT6zNlI{OiEQvF2=	M4fDTHNCVkeHUh?=
Calu-6	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn\tTWM2OD17LkO3OVI5KM7:TR?=	MUPTRW5ITVJ?
LB831-BLC	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTlwNEWxO\|Eh\|ryP	NGrjTIxUSU6JRWK=
SW684	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4L4W2lEPTB;OT60OlEyPiEQvF2=	Mo[0V2FPT0WU
SH-4	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU[4V21jUUN3ME25MlQ6OzZ2IN88US=>	NIHNSYZUSU6JRWK=
IST-MES1	NUmzOnBqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGnVXGpKSzVyPUmuOVE3PDRizszN	NWHQTJltW0GQR1XS
Saos-2	MlXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Moi2TWM2OD17LkWyNVk2KM7:TR?=	NGXGbJNUSU6JRWK=
NCI-H2087	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTlwNkezOVIh\|ryP	MXPTRW5ITVJ?
SCC-9	NUXMO3FkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXfJR\|UxRTlwN{G4NVYh\|ryP	M32yZXNCVkeHUh?=
MFE-280	NIDpO2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{Dp[WlEPTB;OT63Nlc5PSEQvF2=	NWLRSYE2W0GQR1XS
BEN	NHW3N\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{DEe2lEPTB;OT64NlE2QSEQvF2=	NIHVNIJUSU6JRWK=
CP50-MEL-B	MmjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{jvXWlEPTB;OT65NlQ{OiEQvF2=	MlvtV2FPT0WU
SK-MEL-28	NX7KepV1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEfGUWlKSzVyPUGwMlAyQTNizszN	M1\3VHNCVkeHUh?=
NCI-H2452	MlPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{LyPGlEPTB;MUCuNVYh\|ryP	NIS2U3BUSU6JRWK=
NCI-H1395	M{f3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnOxTWM2OD1zMD6xO\|gh\|ryP	M3nVbnNCVkeHUh?=
NCI-H2052	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3;ZUmlEPTB;MUCuNVg5OiEQvF2=	MV\TRW5ITVJ?
A375	M{DpVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE\6dJNKSzVyPUGwMlI1PTJizszN	MVHTRW5ITVJ?
HCC38	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkHyTWM2OD1zMD6zNlIh\|ryP	MVrTRW5ITVJ?
LK-2	M{X0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH7TcWNKSzVyPUGwMlQzODhizszN	NELyUmNUSU6JRWK=
SF126	NEjubJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmnsTWM2OD1zMD60O\|I4KM7:TR?=	M1rqW3NCVkeHUh?=
SK-MEL-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIHvZZhKSzVyPUGwMlc5OzhizszN	MlzkV2FPT0WU
ACN	NVP4e3Q6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYjLTFgxUUN3ME2xNE45Pjd7IN88US=>	NUCzXYM2W0GQR1XS
BB30-HNC	M{fEZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTFyLki3NVEh\|ryP	NEfOTZBUSU6JRWK=
NCI-H747	MkTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2PkXWlEPTB;MUCuPFc1PiEQvF2=	M{HxcXNCVkeHUh?=
KYSE-150	NHi2OnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTFzLkCzPFch\|ryP	MmfDV2FPT0WU
D-247MG	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWq4bWpbUUN3ME2xNU4yODB7IN88US=>	NUS5fZQyW0GQR1XS
BxPC-3	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4j6Z2lEPTB;MUGuN\|c1PyEQvF2=	M2\EVXNCVkeHUh?=
SK-MEL-30	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4r4cWlEPTB;MUGuOFA4QSEQvF2=	NYTuOIpoW0GQR1XS
CAS-1	MnjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHjDeGJKSzVyPUGxMlQyODlizszN	MYrTRW5ITVJ?
no-10	M1G2[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmPNTWM2OD1zMj6xNlE4KM7:TR?=	M2PNNnNCVkeHUh?=
NCI-H2405	MkD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXJR\|UxRTF{LkKwN\|Yh\|ryP	MnGxV2FPT0WU
KGN	M{j1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV;JR\|UxRTF{LkK5NFEh\|ryP	NYnGR5ByW0GQR1XS
BB49-HNC	NXP4U\|VYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWj5OFZLUUN3ME2xNk4{QTV4IN88US=>	NXHrZmlHW0GQR1XS
NCI-H1693	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIH5TWFKSzVyPUGyMlU5OTZizszN	MUfTRW5ITVJ?
RO82-W-1	M2Tpemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTSTWM2OD1zMz6wOlQ6KM7:TR?=	MoLnV2FPT0WU
CAL-85-1	M3:yNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF[5bmJKSzVyPUGzMlQ{QTlizszN	MnLuV2FPT0WU
H-EMC-SS	NEjDSoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{XtW2lEPTB;MUOuPVExPCEQvF2=	NILTb3RUSU6JRWK=
SW1783	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGnocFlKSzVyPUG0MlI{QTFizszN	NWTJbFhTW0GQR1XS
LB771-HNC	MlS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWHTZpd{UUN3ME2xOE41OTlizszN	M3vUdnNCVkeHUh?=
HCC70	NVzn[nVzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{TYcmlEPTB;MUSuOFI{OyEQvF2=	MmXnV2FPT0WU
KNS-81-FD	NV7v[oRRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoHxTWM2OD1zND63NFQ2KM7:TR?=	MYHTRW5ITVJ?
KYSE-520	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1[xRmlEPTB;MUSuPVI4KM7:TR?=	M3LuVnNCVkeHUh?=
TGBC24TKB	M3v3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTF2Lkm1N\|kh\|ryP	MlzBV2FPT0WU
SNB75	MlvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTF3LkC3Nlkh\|ryP	NFG3RW5USU6JRWK=
SW872	Ml7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVPsdphPUUN3ME2xOU4zOjF6IN88US=>	M4C5cnNCVkeHUh?=
U031	NImzUGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmfWTWM2OD1zNT64NFI5KM7:TR?=	NFX0PYRUSU6JRWK=
ChaGo-K-1	NYH6eGwzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIS3VllKSzVyPUG1Mlg{PTlizszN	MYfTRW5ITVJ?
NCI-H441	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn;hTWM2OD1zNj6wNFM6KM7:TR?=	MXLTRW5ITVJ?
TE-12	M3PBZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTF4LkG4O\|Mh\|ryP	NIDjR5ZUSU6JRWK=
NCI-H1755	NGDCcWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVHHSZZ1UUN3ME2xOk42PzNizszN	M1nzW3NCVkeHUh?=
KNS-42	M132OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmHWTWM2OD1zNj62OVg6KM7:TR?=	Mn\XV2FPT0WU
SK-PN-DW	NYnRZm53T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkXrTWM2OD1zNz60NlAyKM7:TR?=	NEDCbZpUSU6JRWK=
NCI-H226	M1\xPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NW\VboI6UUN3ME2xO{46OzR3IN88US=>	MXnTRW5ITVJ?
K-562	Mn\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4XDfGlEPTB;MUiuOlMyPyEQvF2=	NXTyNVRbW0GQR1XS
A388	MmLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUX4XopwUUN3ME2xPU4xOzB\|IN88US=>	NGjqV\|dUSU6JRWK=
ZR-75-30	NEPBcGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1rjS2lEPTB;MUmuNFk3QCEQvF2=	NWj5cHN{W0GQR1XS
LU-135	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYLJR\|UxRTF7LkK2N\|Yh\|ryP	M{\kVXNCVkeHUh?=
NCI-H2029	Mmr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTF7Lk[wNlEh\|ryP	Ml7CV2FPT0WU
HT-1197	NWS0V4RMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX36SGxMUUN3ME2xPU46OjJ5IN88US=>	M{mxUnNCVkeHUh?=
IGR-1	MnHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTJyLkOxNVch\|ryP	Mk\JV2FPT0WU
U-87-MG	NXyzcXJMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV7JR\|UxRTJyLk[0NVMh\|ryP	MVXTRW5ITVJ?
NCI-H1304	NIH5T2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVzCUWN1UUN3ME2yNE44PTBzIN88US=>	MlrqV2FPT0WU
RCC10RGB	MoG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoX3TWM2OD1{MT6yPFI6KM7:TR?=	MXnTRW5ITVJ?
NCI-H520	NYPsd3JpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVfRPIZUUUN3ME2yNk44PjFzIN88US=>	NIDoOWNUSU6JRWK=
SK-LU-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1fUN2lEPTB;MkOuNFcyQCEQvF2=	MmHVV2FPT0WU
UACC-893	NHTQTVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVz4TJNNUUN3ME2yN{4yODN6IN88US=>	MW\TRW5ITVJ?
NCI-H2347	MnXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIW3dIJKSzVyPUKzMlI3PzRizszN	MVzTRW5ITVJ?
U-118-MG	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHjpWpRKSzVyPUKzMlczOTdizszN	MoHCV2FPT0WU
NCI-H596	MoHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFLlVWdKSzVyPUKzMlkxPTVizszN	MorRV2FPT0WU
MZ1-PC	M4TQUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTJ2Lk[3OVkh\|ryP	MnTEV2FPT0WU
SW1417	M1H1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWfJR\|UxRTJ3LkK0PVgh\|ryP	NIHJXHlUSU6JRWK=
NCI-H82	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHfVbnpKSzVyPUK2MlQzQDhizszN	NVnZcJF1W0GQR1XS
COLO-678	NFXFcZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYDBWZRXUUN3ME2yO{41QTF7IN88US=>	NFf5c2FUSU6JRWK=
KURAMOCHI	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnnLTWM2OD1{OD6xNlYh\|ryP	Mmf4V2FPT0WU
NCI-H1650	Mni5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzFZWQyUUN3ME2zNE4yQTJ2IN88US=>	NYHnVXdNW0GQR1XS
HCC1954	NWOyUodYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkexTWM2OD1\|MT6zOlY3KM7:TR?=	NXrzVVVvW0GQR1XS
GAK	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEnXcXJKSzVyPUOyMlI3OTZizszN	NIOwOmVUSU6JRWK=
YAPC	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlXZTWM2OD1\|Mz63OlQ5KM7:TR?=	MUTTRW5ITVJ?
NCI-H2228	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWrDUlB{UUN3ME2zOE4{PjB3IN88US=>	MmjOV2FPT0WU
VMRC-RCZ	M1vGNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIHGfZRKSzVyPUO2MlMxOjJizszN	M1HZUnNCVkeHUh?=
NMC-G1	MoWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWLnTnV5UUN3ME2zO{4xPTJ7IN88US=>	MYnTRW5ITVJ?
D-336MG	NHK1eHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlnjTWM2OD12MT64OFQzKM7:TR?=	Mn;lV2FPT0WU
UACC-62	NWjJZ\|duT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYjKOolUUUN3ME20Nk42PTB3IN88US=>	MmT0V2FPT0WU
C-33-A	Ml7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4m0OGlEPTB;NEWuN\|I2PiEQvF2=	MVjTRW5ITVJ?
HCC1937	NF3sUZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUXUSXpzUUN3ME20O{4yQTV6IN88US=>	NY\OcppWW0GQR1XS
HDLM-2	MkjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWPMUVJSUUN3ME20O{4zOjh5IN88US=>	NIH5O3pUSU6JRWK=
NCI-H727	M4HMZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MojMTWM2OD12Nz6yOFUyKM7:TR?=	MV7TRW5ITVJ?
NY	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRTR7LkO5NFgh\|ryP	Mn;IV2FPT0WU
NCI-H2291	NHnZTpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkLtTWM2OD12OT64N\|AyKM7:TR?=	MnuzV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo

Administration of Vorinostat (~100 mg/kg/day) significantly inhibits the growth of CWR22 human prostate xenografts in nude mice with tumor reductions of 78%, 97% and 97%, at doses of 25 mg/kg/day, 50 mg/kg/day and 100 mg/kg/day, respectively, compared with control. Vorinostat induces the accumulation of acetylated core histones and prostate-specific antigen mRNA expression in CWR22 cells, resulting in higher levels of serum prostate-specific antigen than predicted from tumor volume alone. ^[2] Oral administration of Vorinostat (0.67g/L) crosses the blood-brain barrier, increases histone acetylation in the brain, and dramatically improves the motor impairment in the R6/2 mice model of Huntington's disease. ^[5]

Protocol

Kinase Assay: ^[1]	+ Expand Immunoprecipitation-HDAC assays: The lysate of Jurkat cells is incubated for 1 hour on ice and cleared by centrifugation at 12,000 g for 10 minutes at 4 °C. Supernatants are precleared with 30 μL of 50% protein G-Sepharose slurry for 1 hour at 4 °C. Beads are pelleted by centrifugation and supernatants are incubated for 1 hour at 4 °C with 10 μg of IgG fraction from anti-HDAC1 or HDAC3 polyclonal antisera (preincubated 2 hours at room temperature with either the homologous or heterologous immunizing peptide). Both antisera are raised in rabbits against the carboxylterminal peptide of HDAC1 and HDAC3 by using synthetic peptides coupled to keyhole limpet hemocyanin. 30 μL of 50% protein G-Sepharose slurry is added for 1 hour at 4 °C. Immune complexes are pelleted by centrifugation and washed three times with 1 mL of lysis buffer. Beads are resuspended in 200 μL of HDAC buffer (20 mM Tris-HCl, pH 8.0/150 mM NaCl/10% glycerol), and the HDAC assay is performed with an ³H-acetylated peptide corresponding to amino acids 1-24 of histone H4. Released [³H]acetic acid is quantified by scintillation counting. For inhibitions studies, the immunoprecipitated complexes are preincubated with the different concentrations of Vorinostat for 30 minutes at 4 °C.
Cell Research: ^[2]	+ Expand Cell lines: LNCaP, PC-3, and TSU-Pr1 Concentrations: Dissolved in DMSO, final concentrations ~7.5 μM Incubation Time: 1, 2, 3 and 4 days Method: Cells are exposed to various concentrations of Vorinostat for 1, 2, 3 and 4 days. Cell viability is assessed by trypan blue dye exclusion. (Only for Reference)
Animal Research: ^[2]	+ Expand Animal Models: Male BALB/c nude (nu/nu) mice implanted with CWR22 tumor cells Formulation: Dissolved in DMSO Dosages: ~100 mg/kg/day Administration: Injection i.p. (Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	52 mg/mL (196.74 mM)
	Ethanol	3 mg/mL (11.35 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Vorinostat (SAHA, MK0683) SDF

Molecular Weight	264.3
Formula	C₁₄H₂₀N₂O₃
CAS No.	149647-78-9
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	SAHA, MK0683, suberoylanilide hydroxamic acid

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-10-19)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01281176	Active not recruiting	Adult Solid Neoplasm	National Cancer Institute (NCI)	February 9 2011	Phase 1
NCT01189266	Active not recruiting	Anaplastic Astrocytoma\|Anaplastic Oligoastrocytoma\|Brain Stem Glioma\|Childhood Glioblastoma\|Giant Cell Glioblastoma\|Gliosarcoma\|Untreated Childhood Anaplastic Astrocytoma\|Untreated Childhood Anaplastic Oligoastrocytoma\|Untreated Childhood Brain Stem Glioma\|Untreated Childhood Giant Cell Glioblastoma\|Untreated Childhood Gliosarcoma	National Cancer Institute (NCI)	August 9 2010	Phase 1\|Phase 2
NCT00703664	Completed	Recurrent Mantle Cell Lymphoma\|Recurrent Non-Hodgkin Lymphoma	National Cancer Institute (NCI)	July 9 2008	Phase 2
NCT03198559	Suspended	HIV Infections	The Peter Doherty Institute for Infection and Immunity\|Merck Sharp & Dohme Corp.\|The Alfred\|University of Melbourne	August 8 2017	Phase 1\|Phase 2
NCT02538510	Active not recruiting	Head and Neck Squamous Cell Carcinoma\|Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma\|Recurrent Nasopharynx Carcinoma\|Recurrent Salivary Gland Carcinoma\|Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary\|Stage III Major Salivary Gland Carcinoma\|Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma\|Stage III Nasopharyngeal Carcinoma\|Stage IV Nasopharyngeal Carcinoma\|Stage IVA Major Salivary Gland Carcinoma\|Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma\|Stage IVB Major Salivary Gland Carcinoma\|Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma\|Stage IVC Major Salivary Gland Carcinoma\|Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma	University of Washington\|National Cancer Institute (NCI)	October 8 2015	Phase 1\|Phase 2
NCT01983969	Completed	Advanced Cancers\|Lymphoma	M.D. Anderson Cancer Center	November 7 2013	Phase 1\|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What’s the recommendation about reconstitution of the compound for in vivo animal study?
Answer:
We recommend the following vehicle for S1047: 2% DMSO, 40% PEG 300, 5% Propylene glycol, 1% Tween 80 at 5 mg/mL.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Selective HDAC Inhibitor

RGFP966 : HDAC3-selective, IC50=80 nM.
Selective HDAC Inhibitor

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products5

LMK-235 ^New

LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
CAY10603 ^New

CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
4SC-202 ^New

4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Panobinostat (LBH589)

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.
Entinostat (MS-275)

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Romidepsin (FK228, Depsipeptide)

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
RGFP966

RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold).
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Vorinostat (SAHA, MK0683)

Cited by 100 Publications

20 Customer Reviews

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Vorinostat (SAHA, MK0683) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-10-19)

Tech Support

Frequently Asked Questions

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products5

Choose Your Country or Region

By Signaling Pathways

By product type

Vorinostat (SAHA, MK0683)

Cited by 100 Publications

20 Customer Reviews

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Vorinostat (SAHA, MK0683) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-10-19)

Tech Support

Frequently Asked Questions

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products5

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)